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ABSTRACT OF THE DISSERTATION
THE EFFECT OF VITAMIN D SUPPLEMENTATION ON CARDIOVASCULAR
RISK FACTORS AMONG MINORITIES WITH TYPE 2 DIABETES
by
Joel Exebio
Florida International University, 2015
Miami, Florida
Professor Fatma Huffman, Major Professor
The aim of the present study was to determine the effect of vitamin D supplementation
(4000 IU or 6000 IU of cholecalciferol daily for 6 months) on fasting plasma glucose,
fasting insulin, glycated hemoglobin, and lipid profile in a sample of African-Americans
and Hispanics with T2D and vitamin D insufficiency. Seventy five participants were
recruited by community outreach. Plasma glucose concentration was measured by
hexokinase enzymatic method. Glycated hemoglobin was measured by the DCA2000+
system. Insulin in fasting blood was determined by radioimmunoassay. Plasma total
cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein
cholesterol were assayed by enzymatic methods. Serum vitamin D concentrations were
measured with an enzyme-immunoassay kit. Mixed model was used to compare
treatment effects and Bonferroni multiple comparison tests was used to detect significant
changes from baseline, 3 months, and 6 months on the outcome variables. Significant
improvements in serum 25(OH)D levels were seen from baseline to 3 month and 6
months respectively in both treatments (from 22.25 ± 7.19 to 37.34 ± 12.31 and 37.99 ±
13.22, P<0.05 in the 4000 IU group; from 23.74 ± 5.09 to 43.20 ± 15.94 and 40.62 ±
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19.39, P<0.05 in the 6000 IU group). No significant changes were observed for fasting
plasma glucose, insulin or A1C between groups and within groups. A significant decrease
in total cholesterol for the 6000 IU group at 6 months (from 193.88 ± 41.03 to 183.48 ±
47.53 mg/dl, P=0.040) was observed. Similarly, a significant change in serum
triglycerides was observed at 6 months in the 6000 IU group (from 201.44 ± 91.35 to
172.92 ± 76.87 mg/dl, P=0.037). However, when the model was adjusted for
confounders, significance was lost. Vitamin D supplementation did not improve glucose
homeostasis in this sample. The positive effect of vitamin D supplementation on lipid
profile may be mediated by other cofactors related to vitamin D metabolism.

vi

TABLE OF CONTENTS
CHAPTER

PAGE

CHAPTER I: INTRODUCTION .........................................................................................1
Type 2 Diabetes in the US Population and Mechanism of Action ..........................1
Vitamin D in the US and Mechanism of Action ......................................................2
Type 2 Diabetes and Vitamin D...............................................................................3
Cross Sectional Studies ............................................................................................3
Intervention Studies .................................................................................................3
Type 2 Diabetes, Cardiovascular Disease and Vitamin D .......................................6
Vitamin D Repletion in Participants with Type 2 Diabetes .....................................7
Factors that Affect Vitamin D Insufficiency ...........................................................8
Sun Exposure ...........................................................................................................9
Skin Color ..............................................................................................................10
Vitamin D Intake....................................................................................................11
Specific Aims and Hypotheses ...............................................................................13
References ..............................................................................................................16
CHAPTER II: THE EFFECT OF VITAMIN D SUPPLEMENTATION ON BLOOD
LIPIDS IN MINORITIES WITH TYPE 2 DIABETES ....................................................22
CHAPTER III: THE EFFECT OF VITAMIN D SUPPLEMENTATION ON
GLUCOSE HOMEOSTASIS IN MINORITIES WITH TYPE 2 DIABETES .................40
CHAPTER IV: VITAMIN D REPLETION IN MINORITIES WITH TYPE 2
DIABETES AND COEXISTENT VITAMIN D INSUFFICIENCY ................................59
CHAPTER V: VALIDATION OF A SUN EXPOSURE QUESTIONNAIRE IN
PARTICIPANTS WITH TYPE 2 DIABETES RESIDING IN SOUTH FLORIDA ........76
CHAPTER VI: VALIDATION OF A SHORT FOOD FREQUENCY
QUESTIONNAIRE FOR THE ASSESSMENT OF VITAMIN D INTAKE IN
MINORITIES WITH TYPE 2 DIABETES .......................................................................92
CHAPTER VII: SUMMARY AND CONCLUSIONS ...................................................111
CHAPTER VIII: STRENGTHS AND LIMITATIONS ..................................................114
CHAPTER IX: FUTURE RESEARCH...........................................................................116
APPENDICES .................................................................................................................117
VITA ................................................................................................................................136

vii

LIST OF TABLES
TABLE

PAGE

CHAPTER II
1. Baseline characteristics of participants prior to vitamin D repletion treatments...35
2. Group comparisons of metabolic parameters at different time points without
adjusting for covariates…….. ……………………………………………………36
3. Group comparisons of metabolic parameters at different time points adjusting
for covariates…………...…………………………………………………...........37
CHAPTER III
1. Baseline characteristics of participants prior to vitamin D repletion treatments...53
2. Group comparisons of metabolic parameters at different time points without
adjusting for covariates…………………………………………………………..54
3. Group comparisons of metabolic parameters at different time points adjusting
for covariates……...……………………………………………………………...55
CHAPTER IV
1. Baseline characteristics of participants prior to vitamin D repletion treatments...71
2. Effect of vitamin D repletion treatments on serum vitamin D and parathyroid
hormone………………………………………………………………………….72
3. Relationship between change in parathyroid hormone, change in serum
25(OH)D, and covariates at 3 months for the 4000 IU treatment……...………...73
4. Relationship between change in parathyroid hormone, change in serum
25(OH)D, and covariates at 6 months for the 4000 IU treatment………...……...73
CHAPTER V
1. Characteristics of the study participants at screening (n=90)……………………88
2. Correlation analysis (n=90)……………………………………………………...89
3. Relationship of serum 25(OH)D and covariates…………………………………89

viii

CHAPTER VI
1. Characteristics of the study participants (n=75)………………………………..106
2. Dietary vitamin D intake derived from the long FFQ and short FFQ, and
correlation between methods…………………………………………………...107
3. Cross-classification analysis to determine proportion of participants classified
into the same, or same ± 1quartile based on short FFQ and long FFQ intakes...107
4. Relationship of serum 25(OH)D, dietary vitamin D intake, and covariates……108

ix

ABBREVIATIONS AND ACRONYMS
T2D

Type 2 Diabetes

US

United States

A1C

Glycated Hemoglobin

NHANES

National Health and Nutrition Examination Survey

25 (OH)D

Serum Vitamin D

VDR

Vitamin D Receptor

IR

Insulin Resistance

CVD

Cardiovascular Disease

LDL

Low Density Lipoprotein

UVB

Ultra Violet B

FFQ

Food Frequency Questionnaires

HIV

Human Immunodeficiency Virus

IRB

Institutional Review Board

FIU

Florida International University

PTH

Parathyroid Hormone

HDL

High Density Lipoprotein

RPM

Revolutions Per Minute

BMI

Body Mass Index

SFFQ

Short Food Frequency Questionnaire

RDA

Recommended Dietary Allowance

FPG

Fasting Plasma Glucose

VLDL

Very Low Density Lipoprotein

x

CHAPTER I: INTRODUCTION

Type 2 Diabetes in the US Population and Mechanism of Action
Type 2 diabetes (T2D), the most common form of diabetes (90-95% of all cases)
has increased dramatically in the United States (US) among adults 20 years of age and
older from 9% in 1988 to 12.3% in 2012. Minorities, particularly African Americans and
Hispanics, are disproportionately afflicted by T2D compared to non-Hispanics Whites.
For instance, while the age-adjusted incidence of T2D in non-Hispanics Whites was 7.6%
in 2012, it was 13.2% for non-Hispanic blacks and 12.8% for Hispanics (1).
The food that we eat is digested and absorbed in the gastrointestinal tract. Glucose
is one of the main byproducts of the digestive process. Glucose is transported in the blood
to different organs where it is used as the main fuel source for cell functioning. Insulin
produced by the beta cells of the pancreas is needed to activate the transporters and
receptors that let glucose enter the cells. Type 2 diabetes is characterized by the
diminished capacity of the beta cells to produce sufficient insulin and by the reduction in
number of beta cells (2).
Many genetic and life style factors are associated with the onset of T2D. For
instance, some individuals may have a decreased number of beta cells early in life
predisposing them to the development of T2D. Smoking, obesity, lack of physical
activity, a high calorie diet, stress, and other genetic and environmental factors lead to
dyslipidemia, increased circulating leptin and cytokine levels which have a negative
effect on beta cell function (2).
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Monitoring diabetes outcomes (fasting blood glucose, insulin and glycated
hemoglobin (A1C) and cardiovascular disease risk factors (dyslipidaemia, obesity, and
inflammation) is important for persons with diabetes. Poor diabetes outcomes can lead to
complication such as heart disease, stroke, high blood pressure, blindness, kidney disease
and nervous system disorders.

Vitamin D in the US and Mechanism of Action
Low levels of vitamin D are prevalent in the US. According to data from the
National Health and Nutrition Examination Surveys (NHANES) in 2001-2006, 33% of
the general US population had serum 25(OH)D below 50 nmol/L. In addition, low
vitamin D levels are common among minorities. For instance, 41% of African Americans
and 33% of Mexican Americans had serum 25(OH)D below 50 nmol/L compared to 18%
of non-Hispanic Whites (3).
Humans produce vitamin D in the skin by the action of ultraviolet light. Vitamin
D can also be obtained from the diet from plant and animal sources. The plant form is
vitamin D 2 (ergocalciferol) and the animal form is vitamin D 3 (cholecalciferol). Vitamin
D 3 needs to be activated by hydroxylation in the liver and kidney to form its
metabolically active form: 1,25(OH) 2 D 3 . This metabolite produces some of its effects by
activating the vitamin D receptor (VDR) in the cells (4).
With respect to diabetes, the VDRs have been found in pancreatic tissue
(exclusively in the insulin-producing beta cells). Activated Vitamin D (1,25(OH) 2 D 3 )
binds to the VDR in the beta cells and modulates the transcription of genes signaling the
production of insulin and other proteins important for beta cell function. Different VDR
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gene variances are present in different ethnicities and may predispose to the development
of type 2 diabetes (5). These variances may explain, in part, the high incidence of type 2
diabetes among African Americans and Hispanic.

Type 2 Diabetes and Vitamin D
Cross Sectional Studies
Several associations between low vitamin D levels and incidence of metabolic
disorders have been reported in recent years. For instance, poor vitamin D status has been
found in persons at risk or with T2D, however, the nature of this relationship is not clear
(6, 7). Similarly, a negative association between vitamin D levels and insulin resistance
has been reported in a large sample representative of the US adult population and in
participants at risk for T2D (7, 8). According to these results vitamin D levels are
associated with insulin sensitivity and insulin resistance. The mechanism of action of
vitamin D is not clear because most studies to date have been conducted in patients
without diabetes.

Intervention Studies
Vitamin D supplementation in participants without diabetes had a positive effect
on insulin secretion and insulin resistance (9). Similar results have been found in vitamin
D deficient animals (10). Since patients with T2D not only have a high prevalence of
vitamin D deficiency, but also, other cardiovascular risk factors that may interact with
vitamin D homeostasis, it is difficult to extrapolate results from patients without diabetes.
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This scenario has increased the interest in the role that vitamin D may play in
glucose homeostasis among patients with T2D, which includes insulin resistance and
glycemic control. In fact, several interventional studies providing vitamin D to
participants at risk or with T2D have been conducted that have found inconsistent results
(11-15). Borissova et al (11) examined the effect of vitamin D 3 supplementation on
insulin resistance and insulin secretion in 10 patients with T2D. Seventeen age and
gender-matched individuals without T2D served as controls. The intervention group
received 1332 IU of cholecalciferol daily for 1 month. Fasting plasma insulin secretion
increased significantly by 34.3%, however, the decrease in insulin resistance was not
significant. A small sample size and short duration of treatment are the major limitations
of this study. In another study, however, vitamin D supplementation in men with T2D
improved insulin secretion (12, 13). Inomata et al. (12) provided 2ug/d (80 IU/day) of
alphacalcidiol versus placebo to 14 Japanese males with T2D, mean age 54.3 years for 3
weeks. The area under the oral glucose tolerance test curve was used as a measure of
insulin secretion. Results showed improved insulin secretion. Limitations of this study
are the lack of measure of plasma vitamin D concentrations and the small sample size.
Similarly, Orwoll et al. (13) provided 1ug/d (40 IU/d) of 1,25(OH) 2 D versus placebo to
35 adults with recently diagnosed T2D (within 3 years) for 14 days, with mean age of 61
years. Insulin secretion was determined from the area under the glucose tolerance test
after a meal challenge. A tendency for better insulin secretion was observed. Main
limitations of this study were the short duration of the intervention and the lack of
assessment of serum vitamin D post-intervention. Persons with T2D and low serum
25(OH)D had improvements in glycemic control with 3000 IU of vitamin D 3 for 6 and 9
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months (14). In contrast, Jorde et al. (15) provided 40000 IU per week versus placebo to
32 participants with T2D for 6 months. No significant change on insulin, fasting plasma
glucose or A1C was noted. Participants in this study were not vitamin D deficient,
suggesting that vitamin D supplementation may have no effect on people who are not
vitamin D deficient. Conflicting reports may be a consequence of different characteristics
of the populations, inadequate dosages, different forms of vitamin D supplements used,
short duration of the studies, different outcome variables, and lack of control of serum
vitamin D levels pre and post intervention.
The vast majority of these studies have been conducted in non-Hispanic White
populations. Prevalence of hypovitaminosis D however, is found to be higher in Blacks
and Hispanics as compared to Whites (16-18). According to data from the Center for
Disease Control and Prevention, 20% of Mexican Americans and 46% of African
Americans had blood vitamin D levels lower than non-Hispanic Whites across age
categories (19). Vitamin D levels decrease with increasing age. While vitamin D levels
fall 1.6% from 60 nmol/L to 59 nmol/L for ages 6-59 years for non-Hispanic Whites, it
falls 34.7% from 46 nmol/L to 30 nmol/L for African Americans and 20% from 56
nmol/L to 45 nmol/L for Mexican Americans in the same age range (19). While T2D is a
multifactorial disease, evidence from observational studies and small clinical trials
indicate possible improvements of T2D symptoms with vitamin D supplementation.
Since minorities such as African Americans and Hispanics have higher risk of both T2D
and vitamin D deficiency as compared to Caucasians (20), it is important to determine the
effect of vitamin D supplementation in these high risk populations.
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Type 2 Diabetes, Cardiovascular Disease and Vitamin D
The literature indicates that patients with T2D and insulin resistance (IR) are more
likely to develop arteriosclerosis and all of the complications related to this condition,
such as myocardial infarction and stroke (21). In fact, vitamin D receptors are present in
many cardio vascular target organs regulating cell differentiation, proliferation and
function (22). Although patients with T2D usually have other risk factors for
arteriosclerosis, associations among vitamin D levels and several risk factors for
cardiovascular disease (CVD) have been documented. Martins et al. (23) demonstrated a
strong association between hypovitaminosis D and cardio-vascular outcomes in a sample
of 13,000 US adults using data from the Third National Health and Nutrition
Examination Survey. After controlling for confounders, the prevalence of hypertension
(OR=1.30), T2D (OR=1.98), obesity (OR=2.29), and high triglyceride levels (OR=1.47)
was significantly higher in the first quartile compared to the fourth quartile of serum
25(OH)D levels (P<0.001 for all) demonstrating a high likelihood of association between
vitamin D levels and several cardio vascular risk factors.
Similarly, Skaaby et al. (24), conducted a large prospective evaluation of serum
vitamin D levels and blood lipids. They found a strong association between lower
25(OH)D level and elevated total cholesterol. The changes in lipid profile associated with
a variation in vitamin D status, however, were small and without clinical significance. In
addition, since obesity and ethnicity are risk factors for both vitamin D insufficiency and
dyslipidemia, other confounding variables that may affect this relationship should not be
excluded.
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Randomized clinical trials evaluating the effects of vitamin D repletion on lipid
profile have reported conflicting results (25-27). Ponda et al. (25), assigned 151 vitamin
D deficient adults at high risk of CVD to either 50,000 IU/week of vitamin D 3 or placebo
for 8 weeks. No improvements on lipid profile were noted. On the contrary, a significant
increase in LDL cholesterol was reported. The authors remarked that vitamin D
supplementation may be dangerous for participants at risk of CVD. In contrast, Alkharfy
et al. (26), examined the effect of 2000 IU/day vitamin D 3 supplementation on 499 Saudi
participants with type 2 diabetes on diet, insulin or oral hypoglycemic agents and
compared them with a non-diabetic control group. Significant reductions in total
cholesterol, triglycerides, and systolic blood pressure were found in the treatment groups
receiving insulin and oral hypoglycemic agents. Similarly, Al-Daghri et al. (27),
evaluated the effect of 2000 IU/day vitamin D 3 supplementation on participants with type
2 diabetes over a 12 month period. Significant decreases in total cholesterol and LDL
were shown mainly in women.
Since finding new strategies to decrease diabetes complications and
cardiovascular risk among patients with T2D is a major public health goal, testing the
direct benefit of vitamin D repletion on cardio vascular risk factors is warranted.

Vitamin D Repletion in Participants with Type 2 Diabetes
Protocols for correction of vitamin D insufficiency in patients with cystic fibrosis,
chronic kidney disease, hyperparathyroidism, osteoporosis and pregnancy have been
published (28-32). There is no standard method that has been developed for the repletion
of vitamin D insufficiency in subjects with T2D yet.
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Recently, the Endocrine Society announced new clinical practice guidelines of
standard of care vitamin D supplementation for insufficient populations (1500-2000 IU
daily for ages 19-70) to achieve sufficiency (25(OH)D >75 nmol/L) and recommended an
upper limit of 4000 IU as the threshold for safety in healthy individuals. In addition, all
adults who are vitamin D deficient (25(OH)D < 50 nmol/L) are recommended to
supplement with 6000 IU/d of vitamin D 3 until sufficiency is reached, followed by a
maintenance therapy of 2000 IU/d. In obese patients, and patients taking medications that
interfere with vitamin D metabolism, the suggested therapy is to supplement with 600010000 IU/d of vitamin D 3 until sufficiency is reached, followed by a maintenance therapy
of 3000-6000 IU/d (33). The optimal vitamin D supplementation that is required to
improve insulin resistance and glycemic control for special populations, including those
with elevated insulin resistance, type 2 diabetes, and individuals with dark skin color with
vitamin D insufficiency has not been determined. Therefore, it is important to test if the
new standard of care has an impact on the glucose control of African Americans and
Hispanics, or if higher dosages are needed. There is concern that vitamin D repletion
regimens, however, may produce toxicity. Serum 25(OH)D levels > 150 ng/ml have been
used as the threshold for toxicity (34).

Factors that Affect Vitamin D Insufficiency
Other factors that may contribute to the high prevalence of vitamin D
insufficiency in persons with T2D are high melanin levels, lack of sun exposure,
inadequate diet, obesity, and genetic predisposition to vitamin D insufficiency (35).
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Sun Exposure
In a tropical area such as South Florida, it is taken for granted that everybody will
have enough sun exposure. Sun exposure, although, may vary depending on the
profession/job performed, the presence of a disability condition that may keep individuals
inside their homes, exercise habits, etc.
The sun is the main source of vitamin D. Ultraviolet B (UVB) radiation emitted
by the sun is converted to vitamin D in the skin. The avoidance of sun exposure may
explain in part the current vitamin D deficiency epidemic (36).
Research is still in progress to quantify vitamin D status in specific populations
and its relation with several diseases. Therefore, the assessment of vitamin D status must
take into consideration sun exposure behaviors through the use of validated tools.
Sun exposure questionnaires are commonly used to assess UVB exposure because
they are easy to use and inexpensive. Observed sun exposure and dosimetry, an objective
measure of UVB radiation, have been used for comparison (37-40), however, neither of
them is considered a gold standard (41). The correlations among sun exposure
questionnaires and observed exposure or dosimetry have been significant but relatively
low, leaving a big percentage in the variation in UVB unexplained by sun exposure alone
(37-40).
Similarly, when sun exposure questionnaires have been used in models to predict
25(OH)D (the universally accepted biomarker to determine vitamin D status) a large
percentage of the variation was not explained by sun exposure, leading to a
misclassification of vitamin D status if based on sun exposure alone (42-44).
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On the other hand, objective and reliable measures of change in skin color using
scanners which allow in vivo quantification, have shown significantly high correlations
with laboratory induced UVB exposure (r s = 0.99) (45). In addition, these devices offer
high inter/intra rater reliability (46). They may be used as gold standard to validate sun
exposure questionnaires. Therefore, it is necessary to validate sun exposure tools in order
to accurately assess vitamin D status in minorities with T2D.

Skin Color
Even with similar levels of sun exposure, the skin color is a key determinant in
vitamin D production. Each ethnic group has a different skin color: African Americans
having the greatest amount of melanin compared to the majority of Whites who have the
least amount of melanin and the fairest skin tone. African Americans are particularly at
high risk for vitamin D deficiency because their darker skin color limits the amount of
ultraviolet light that penetrates, thereby reducing cutaneous synthesis of vitamin D 3 (47).
Skin pigmentation can reduce the UVB from penetrating the skin by as much as 99%
which has the same effect as applying sunscreen of factor 15 (48). Blood vitamin D
levels in Blacks are lower than in Whites when exposed to the same levels of sun; and,
Blacks are found to have lower serum 25(OH)D concentrations both in winter and in
summer compared to their White counterparts (49, 50). Weaver et al. (51) estimated that
Blacks need 1840–2480 IU/d of vitamin D 3 supplementation, although, this assumption
was based on a single study performed in White adults (52). It may not be a coincidence
that darker-skinned Asian immigrants (who have a greater amount of melanin) have a
four to five times higher prevalence of T2D than their British Caucasian counterparts;
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indicating that increased melanin may cause lower vitamin D status and potential to
contribute to the development of diabetes (53, 54). Therefore, it is important to control
for sun exposure when assessing serum vitamin D levels, not only through surveys, but
also with objective measures of change in skin color.

Vitamin D Intake
Vitamin D level depends on several modifiable and non-modifiable factors. Skin
color is the major non-modifiable factor and modifiable factors include sun exposure and
vitamin D intake (55), however, there are no validated tools to assess vitamin D intake in
participants with type 2 diabetes.
Nutrient intake can be estimated by multiple methods, each of them presenting
their own advantages and disadvantages. Food records are usually considered the gold
standard. They are administered over several days in order to represent usual intake,
although, due to the burden of writing down every food and portion size, the period is
limited (56). If the subject change his/her usual diet during this period, the data may be
misleading. In addition, a tendency to underreport food intake by obese and overweight
individuals have been reported (57). In contrast, food frequency questionnaires (FFQ) can
assess food intake over a longer period of time (usually over a 1 year), can be
administered by dietitians in situ or self-administered in a short period of time putting
less burden on participants and may expose habits not evident on food records (58).
Furthermore, FFQ should include ethnic specific foods and being validated in the specific
population under study (58).
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Several vitamin D FFQs have been validated in different populations, however, to
our knowledge; none have been validated in Hispanic and African American participants
with T2D. Marshall et al. (56) validated the Iowa Study Targeted Nutrient SemiQuantitative Questionnaire and the Block Kids Food Questionnaire for estimating
calcium and vitamin D intake among children using a 3-day food diary as reference.
Correlations between the questionnaires and food diary for vitamin D were modest
(r=0.487 and r=0.512, respectively). Pritchard et al. (59) validated a calcium, vitamin D,
and vitamin K FFQ that also included assessment of supplement intake in overweight and
obese post-menopausal women against a 5-day diet record. A strong correlation between
the FFQ and the diet record for vitamin D was reported (r=0.89). Taylor et al. (58)
validated a FFQ for assessing calcium and vitamin D intake in adolescent girls with
anorexia nervosa against a 4-day food record. Strong correlations among the two diet
collection methods for vitamin D was observed (r=0.78). The analysis was adjusted for
energy intake.
Nucci et al. (55) evaluated the effectiveness of a short FFQ in determining
vitamin D intake against a previously validated long FFQ in a population of 6 to 14 year
old children. Correlations among the questionnaires was modest at baseline and follow up
(r=0.35 and r=0.37, respectively). The study took into consideration the sun exposure
habits of the population. Blalock et al. (60) assessed the validity of a short calcium and
vitamin D FFQ among 27 university employees against a 7 day food diary and a
previously validated long FFQ. Vitamin D intakes from the food diary and short FFQ
were significantly correlated (r=0.72). The positive predictive value for identifying
participants with low vitamin D intake using a cutoff point of 200 IU/day was 100%.

12

It has been suggested that validation of nutrient intake should be conducted
against a previously validated diet record but also against a biomarker of nutrient status
(61). Vitamin D status is determined by serum 25(OH)D levels, however, since UVB
light is the major contributor of vitamin D, validation studies should be conducted during
winter where 25(OH)D will be mainly affected by intake and no sun exposure.
Otherwise, sun exposure should be taken into consideration in the analysis of vitamin D
intake and 25(OH)D.
In this regard, Wu et al. (61) validated a 37-item vitamin D FFQ among a
multiethnic sample of Canadian adults during late winter against a 7-day food diary and
25(OH)D levels. Intakes were modestly correlated among dietary collection methods and
25(OH)D (r=0.529 and r=0.481, respectively). After redefining the serving sizes and
excluding fortified orange juice from the FFQ, the correlations improved (r=0.602 and
r=0.520, respectively).
Since studies suggested that vitamin D deficiency may have a role on insulin
resistance and T2D progression, it is imperative to validate diet collection tools in this
particular population.

Specific Aims and Hypotheses
Specific Aim 1
The aim of the present study was to determine the effect of supplemental vitamin
D intake (4000 IU or 6000 IU of Cholecalciferol daily for 6 months) on fasting plasma
glucose, fasting insulin, A1C, and blood lipids in a sample of African-Americans and
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Hispanics with T2D and vitamin D insufficiency (25(OH)D<30 ng/ml), 30-70 years of
age, and living in South Florida.
Hypothesis 1
Vitamin D supplementation (4000 IU or 6000 IU of Cholecalciferol daily for 6
months) will improve fasting plasma glucose, fasting insulin, A1C, and blood lipids in a
sample of African-Americans and Hispanics with T2D and vitamin D insufficiency
(25(OH)D < 30 ng/ml), 30-70 years of age, living in South Florida.
Specific Aim 2
To evaluate the efficacy and safety of two vitamin D repletion regimens: 4000 IU
and 6000 IU of Cholecalciferol daily for 6 months in a sample of African Americans and
Hispanics with T2D and vitamin D insufficiency (25(OH)D<30 ng/ml), 30-70 years of
age, and living in South Florida.
Hypothesis 2
Serum vitamin D will reach sufficient levels (25(OH)D≥30 ng/ml) in a sample of
African Americans and Hispanics with T2D and vitamin D insufficiency, 30-70 years of
age, living in South Florida; after 6 months of daily supplementation with 4000 IU and
6000 IU of Cholecalciferol with no reported adverse events .
Specific Aim 3
To validate a sun exposure questionnaire against objective measures of change in
skin color and to assess its validity in predicting 25(OH)D status in a sample of African
Americans and Hispanics with T2D.
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Hypothesis 3
The sun exposure questionnaire scores will correlate with the change in skin color
scores due to sun exposure and will predict 25(OH)D status in a sample of African
Americans and Hispanics with T2D.
Specific Aim 4
To expand the short FFQ developed by Blalock et al. (60) to include specific
ethnic foods consumed by Hispanics and African Americans in South Florida and to
examine the criterion validity of the short FFQ by comparing intakes with a previously
validated long FFQ and serum 25(OH)D levels.
Hypothesis 4
The short FFQ questionnaire scores will correlate with a previously validated long
FFQ scores and serum 25(OH)D levels.
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CHAPTER II: THE EFFECT OF VITAMIN D SUPPLEMENTATION ON
BLOOD LIPIDS IN MINORITIES WITH TYPE 2 DIABETES

Introduction
Low levels of vitamin D are prevalent in the US. According to data from the
National Health and Nutrition Examination Surveys (NHANES) in 2001-2006, 33% of
the general US population had serum 25(OH)D below 50 nmol/L. In addition, low
vitamin D levels are common among minorities. For instance, 41% of African Americans
and 33% of Mexican Americans had serum 25(OH)D below 50 nmol/L compared to 18%
of non-Hispanic Whites (1).
Vitamin D is produced in the skin by the action of ultraviolet light. Vitamin D can
also be obtained from the diet with consumption of vegetable and animal products.
Vitamin D needs to be activated by hydroxylation in the liver and kidney to form its
metabolically active form: 1,25(OH) 2 D 3 . This metabolite produces its effects by
activating the vitamin D receptor (VDR) in the cells (2).
The VDR is present in vascular and myocardial cells which suggest an
involvement of vitamin D mediated effects in the development of cardiovascular disease
(CVD) (3). Cardiovascular risk factors such as type 2 diabetes and dyslipidemia are the
major causes of death in the US, especially among minorities (4). Therefore, it is of
crucial importance to determine the role of vitamin D supplementation on the prevention
of CVD.
Associations among vitamin D insufficiency and lower high density lipoprotein
(HDL), higher triglycerides, and hypercholesterolemia have been reported (5-7). Skaaby
et al. (7), conducted a large prospective evaluation of serum vitamin D level and blood
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lipids. They found a strong association between lower serum 25(OH)D level and elevated
total cholesterol. The changes in lipid profile associated with a variation in vitamin D
status, however, were small and without clinical significance. In addition, since obesity
and ethnicity are risk factors for both vitamin D insufficiency and dyslipidemia,
confounding for these variables should not be excluded.
Randomized clinical trials evaluating the effects of vitamin D repletion on lipid
panel have reported conflicting results (8-10). Ponda et al. (8), assigned 151 vitamin D
deficient adults at high risk of CVD to either 50,000 IU/week of vitamin D 3 or placebo
for 8 weeks. No improvements on lipid panel were noted. On the contrary, a significant
increase in low density lipoprotein (LDL) cholesterol was reported. The authors remarked
that vitamin D supplementation may be dangerous for participants at risk of CVD. In
contrast, Alkharfy et al. (9), examined the effect of 2000 IU/day vitamin D 3
supplementation on 499 Saudi participants with type 2 diabetes on diet, insulin or oral
hypoglycemic agents and compared them with a non-diabetic control group. Significant
reductions in total cholesterol, triglycerides, and systolic blood pressure were found in the
insulin and oral hypoglycemic groups. Similarly, Al-Daghri et al. (10), evaluated the
effect of 2000 IU/day vitamin D 3 supplementation on participants with type 2 diabetes
over a 12 month period. Significant decreases in total cholesterol and LDL were shown
mainly in women.
Patients with type 2 diabetes are more likely to develop hypertension,
dyslipidemia, arteriosclerosis and all of the complications related to myocardial infarction
and stroke (11). Since finding new strategies to decrease diabetes complications and
cardiovascular risk among patients with type 2 diabetes is a major public health goal,
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testing the direct benefit of vitamin D repletion on blood lipids is warranted. In addition,
most of the current studies have been conducted in Caucasian populations. Since African
Americans and Hispanics are more prone to both vitamin D insufficiency and type 2
diabetes compared to Caucasians, it is important to test the effect of vitamin D repletion
on these high risk populations.
The aim of the present study was to determine the effect of supplemental vitamin
D intake (4000 IU/day or 6000 IU/day of vitamin D 3 over a 6 month period) on blood
lipids in a sample of African Americans and Hispanics with type 2 diabetes and vitamin
D insufficiency (25(OH)D<30 ng/ml) living in South Florida.

Methods
Subject Recruitment
An intervention study to assess the effects of vitamin D supplementation (4000
IU/day and 6000 IU/day) over six months on cardiovascular disease markers among a
sample of African Americans and Hispanics with T2D was conducted. The present study
analyzed the data collected at screening (serum 25(OH)D), baseline (blood lipids), 3
months (serum 25(OH)D and blood lipids), and 6 months (serum 25(OH)D and blood
lipids).
The study consisted of two phases: phase one included the screening of
individuals, phase two included the recruitment of individuals who met inclusion criteria
and beginning of the vitamin D intervention trial. Inclusion criteria were vitamin D
insufficiency (25(OH)D< 30 ng/ml), 30-70 years of age, African American or Hispanic
with confirmed T2D. Exclusion criteria were taking vitamin D supplements other than
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standard daily multivitamin formula, being pregnant or lactating, having thyroid, hepatic,
renal dysfunction, cancer, HIV, or major psychiatric disorders.
Flyers explaining the purpose of the study, inclusion/exclusion criteria and the
investigators’ emails and phone numbers were distributed in highly visited community
areas such as churches, supermarkets, and clinics. Two clinics were visited every week
for recruitment purposes: Borinquen Health Care Center and Clinical Care Medical
Center. When volunteer participants called the investigators back, purposes of the study
were explained and specific questions were asked to assure compliance with inclusion
criteria. All qualified participants were invited to take part in a morning session at the
Human Nutrition Laboratory at Florida International University (FIU) for fasting blood
sampling to screen for vitamin D insufficiency. The study was approved by IRB at FIU.
All participants were asked to sign an informed consent form previous to screening data
collection. Only participants with confirmed T2D diagnosis by a physician were eligible
for the study. All participants were screened for vitamin D insufficiency in phase one.
They were contacted either to continue in the study or to inform them that they were
disqualified based on their vitamin D levels.
Participants in both groups were required to take either 4000 IU or 6000 IU of
vitamin D (Cholecalciferol) per day given in the form of a pill in a single daily dose.
Compliance was determined by returned pill count at follow ups. When less than 80% of
the pills were taken, the subject was classified as non-compliant. Adverse events were
recorded at each visit. Each participant was seen 4 times; at screening, baseline, 3
months, and 6 months. Serum 25(OH)D was measured at screening, 3 months, and 6
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months. Blood lipids were measured at baseline, 3 months, and 6 months. The time spam
between screening and baseline was one week.
Total study lasted for 25 weeks for each participant from screening to final
assessment. The study started in June 2011 and was completed on September 2013.
Ninety two participants were screened. Seventy five qualified for the intervention (n=50
for 4000 IU/day treatment and n=25 for 6000 IU/day treatment). Three participants
qualified for the study based on their vitamin D status but did not attend the 3 month and
6 month follow ups (all in the 4000 IU group). Eight participants attended the 3 month
but not the 6 month follow up (5 in the 4000 IU and 3 in the 6000 IU group,
respectively). Five participants completed the study but were non-compliant (3 in the
4000 IU and 2 in the 6000 IU treatment, respectively). Since an intent to treat approach
was followed, all 75 participants were included in the present study.

Blood Collection
Venous blood (15 ml) was collected from each subject by a certified phlebotomist
using standard laboratory methods at each study point. After coagulation, blood was
centrifuged at 2500 RPM for 30 minutes. Plasma total cholesterol, triglycerides, LDL,
and HDL cholesterol were assayed by enzymatic methods (Cobas Mira, Roche
Diagnostics, Indianapolis, IN). Serum vitamin D concentrations were measured with an
enzyme-immunoassay kit by absorbance (Immunodiagnostic Systems Scottsdale, AZ).
Vitamin D values were tested at screening, 3 month and 6 month visits. Total cholesterol,
triglycerides, LDL, and HDL cholesterol were tested at baseline, 3 month, and 6 month
visits.
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Socio-demographic Questionnaire
Participants were asked to complete the standard questionnaire on site. Trained
bilingual interviewers (English and Spanish) administered the questionnaires in the
language of preference of the participant. Data were collected using a socio-demographic
questionnaire which included questions related to gender, age, education level, years with
diabetes, smoking, and medication use.

Anthropometric Measurements
Height and weight were measured using a SECA clinical balance scale (Seca
Corp, Columbia, MD). Body mass index (BMI) was calculated as weight in kg/height in
m2. BMI was calculated at baseline, 3 month, and at 6 month visits. Only baseline values
were used for the analysis due to the lack of significant changes in BMI at 3 months and
6 months.

Sun Exposure Questionnaire
The sun exposure questionnaire developed by Hanwell et al. (12) was applied
following the original rubric. Time spent outdoors during the previous week (0≤5
minutes, 1=5-30 minutes and 2≥30 min) was self-reported. Four options for skin exposed
while outdoors were offered (1=face and hands, 2=face, hands and arms, 3=face, hands
and legs and 4=bathing suit). The daily sun exposure score for each day was calculated
by multiplying the time spent outdoors score times the skin exposed while outdoors
score. The scale for each day ranged from 0 to 8. The weekly sun exposure was
calculated by adding the daily scores (min =0, max=56). The questionnaire was
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administered at baseline, 3 months, and 6 months, but because it did not change
significantly, only baseline values were used in the analysis. Since the sun is the main
source of vitamin D, baseline sun exposure may have an effect on our final outcomes.
Therefore, analysis was adjusted for sun exposure.

Skin Color
In order to have an objective measure of sun exposure, skin color was determined
by reflectance colorimetry using the SmartProbe 400 (IMS Inc. USA). This instrument
uses the International Commission on Illumination Scale which ranges from 0 (black) to
100 (white) for skin color. Two readings at each measurement site for each participant
were taken: two on the dorsal aspect of the wrist of the right hand (area most exposed to
sun), two on the inside of the right upper arm (area less exposed to the sun). The mean
values of the two readings at each measurement site were used for analysis. Data were
collected at baseline, 3 months, and 6 months, but because it did not change significantly,
only baseline values were used in the present analysis. Since participants with darker skin
color tend to have lower levels of serum 25(OH)D, skin color may have an effect on lipid
profile. Therefore, analysis of the effect of vitamin D supplementation on lipid panel was
adjusted for skin color.

Assessment of Dietary Intake
Dietary intake was determined using the long food frequency questionnaire (FFQ)
developed by Walter Willett (13). This FFQ has been validated in different ethnic groups
and, also, specifically in Cuban-Americans in South Florida (14). Participants self-
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reported the average consumption of specific amount of foods over the past 12 months.
Frequencies ranged from “never” to “six or more servings per day”. The FFQ also
assessed the frequency use of multivitamin/mineral supplements, salt, sugar, alcohol and
vitamin D intake. The questionnaire was administered at baseline.

Statistical analysis
Descriptive statistics were used for baseline characteristics. Numerical normally
distributed data and categorical data were compared using independent t-test and ChiSquared test, respectively. Intent to treat analysis was used to analyze the effect of
vitamin D on the outcome variables.
Main variables of the study were: plasma total cholesterol, triglycerides, LDL,
and HDL cholesterol. All variables were input as continuous in the analysis. Control
variables included: BMI, gender, age, smoking, years with diabetes, sun exposure score,
vitamin D intake, fasting plasma glucose, lipid lowering medication use, and skin color.
Mixed model was used to compare treatment effects (4000 IU vs. 6000 IU) on the
outcome variables. Bonferroni multiple comparison test was used to detect significant
changes from baseline, 3 months, and 6 months on the outcome variables with and
without adjustment for age, gender, years with diabetes, smoking, BMI, vitamin D intake,
sun exposure score, upper arm skin color, forearm skin color, fasting plasma glucose, and
lipid lowering medication use. Significance was set at p<0.05 and all analyses were two
sided. Statistical analysis was conducted using SPSS 18.0 (Chicago).
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Results
Groups were different at baseline on BMI (34.72 ± 6.98 kg/m2 vs. 30.74 ± 4.93
kg/m2, P=0.013 for 4000 IU and 6000 IU; respectively) and HDL cholesterol (50.64 ±
12.20 mg/dl vs. 42.44 ± 10.40 mg/dl, P=0.004 for 4000 IU and 6000 IU; respectively)
(Table 1).
There was no significant difference between groups regarding serum 25(OH)D
(P=0.225). However, significant improvements in serum 25(OH)D levels were seen from
baseline to 3 month and 6 months, respectively in both treatments (from 22.25 ± 7.19 to
37.34 ± 12.31 and 37.99 ± 13.22, P<0.05 in the 4000 IU group; from 23.74 ± 5.09 to
43.20 ± 15.94 and 40.62 ± 19.39, P<0.05 in the 6000 IU group) (Table 2).
Differences between 3 months and 6 months levels for serum 25(OH)D were not
significant in both treatments (P>0.05). In the 6000 IU group, the value showed a nonsignificant decline at 6 months compared to the 3 months follow up.
In the unadjusted model, the difference between and within groups was significant
for total cholesterol (P=0.027 and P=0.044, respectively). However, the interaction
between time and treatment was not significant (P=0.653) (Table 2). The multiple
comparisons analysis showed a borderline not significant decrease in total cholesterol for
the 4000 IU group at 6 months (from 213.08 ± 42.30 to 199.84 ± 32.79 mg/dl, P=0.052)
and a significant decrease for the 6000 IU group at 6 months (from 193.88 ± 41.03 to
180.48 ± 27.53 mg/dl, P=0.040). However, when the model was adjusted for
confounders, significance was lost (Table 3).
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Similarly, in the unadjusted model (Table 2), a significant change for triglycerides
was observed at 6 months in the 6000 IU group (from 201.44 ± 91.35 to 172.92 ± 76.87
mg/dl, P=0.037). The significance was lost after adjusting for confounders (Table 3).
In the adjusted model, only serum 25(OH)D changed significantly over time
(Table 3). Adherence defined as consumption of more than 80% of supplied vitamin D
pills was 94% for the 4000 IU group and 92% for the 6000 IU group without any
differences between groups. No adverse events were reported during the course of the
study.
Three participants stopped taking lipid lowering medication during the course of
the study due to lack of money to buy the refills (2 in the 4000 IU group and 1 in the
6000 IU group).

Discussion
In the current study, vitamin D 3 supplementation at 6000 IU/day significantly
reduced total cholesterol, and triglycerides in a sample of Hispanics and African
Americans with type 2 diabetes and vitamin D insufficiency. However, the significance
was lost after adjusting for confounders.
In fact, vitamin D insufficiency is related to other cardiovascular risk factors such
as obesity, smoking, and unhealthy diet (15, 16). Regarding the strong association
between obesity and vitamin D insufficiency, it has been hypothesized that vitamin D is
stored in the fat tissue and is not bioavailable in obese participants resulting in low levels
of serum vitamin D despite sufficient intake (15). In this context, if obesity is corrected
we may see improvements in both serum vitamin D levels and lipid profile.
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Our results support this hypothesis. The participants were obese based on BMI
classification. The positive effect of vitamin D supplementation on total cholesterol and
triglycerides observed in the 6000 IU/day group disappeared when the model was
adjusted for covariates such as smoking, age, gender, skin color, sun exposure, lipid
lowering medication, years with diabetes, and BMI. Therefore, our results suggest that
the association between vitamin D insufficiency and dyslipidemia may be mediated by
other cardiovascular risk factors.
Recent clinical trials examining the effect of vitamin D supplementation on lipid
profile among individuals with and without type 2 diabetes and vitamin D insufficiency
have been inconsistent (8,9,17). Some studies have found significant improvements in
lipid profile after vitamin D supplementation. However, none of them adjusted for
covariates in the analysis. Alkharfy et al. (9), randomly assigned 499 participants with
type 2 diabetes to 8 groups: control (n=151), rosiglitazone alone (n=49), diet (n=15),
insulin alone (n=55), insulin + orals (n=12), metformin alone (n=121), oral agents
combination (n=37), and sulphonylurea alone (n=59). Participants received 2000 IU/day
of vitamin D 3 for 12 months. In the insulin alone group, total cholesterol decreased
significantly in women. In the insulin + orals group, triglycerides and total cholesterol
decreased significantly after 12 month. This study provides a view of how vitamin D
supplementation can interact with certain drugs commonly used in patients with type 2
diabetes regarding lipid lowering benefits. In contrast, Ponda et al. (8), randomly
assigned 151 vitamin D deficient participants at high risk for CVD to either 50 000 IU of
vitamin D 3 weekly or placebo. Vitamin D failed to improve lipid profile. In addition, a
significant increase in LDL was noted which significantly correlated with a decrease in
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parathyroid hormone (PTH) levels. Similarly, Salehpour et al. (17), randomly distributed
77 healthy premenopausal overweight and obese women to either 25µg/day of vitamin
D 3 or placebo for 12 weeks. Significant increases in total cholesterol, LDL and HDL
were reported. This study excluded participants taking any antihypertensive and lipid
lowering medication. Since it is difficult to evaluate the effect of vitamin D
supplementation on lipid profile when participants are already taking lipid lowering
medication, this study provided a new insight into the raw metabolic effects of vitamin D.
Authors from the last two studies warned that vitamin D may have both positive and
negative effects on different cholesterol particles. Therefore, it should be monitored and
used with caution among participants at risk of CVD. Conflicting results may be a
consequence of different dosages used, different populations, different duration of
treatment, and lack of control for obesity, physical activity, sun exposure, vitamin D
intake, and medication usage.
Regarding lipid metabolism, studies have shown that vitamin D can reduce
hepatic triglyceride synthesis and increase uptake by peripheral tissues due to increased
intestinal calcium absorption (18, 19). Similarly, vitamin D promotes the formation of
large HDL particles due to an increase in apolipoprotein A1, which increases reverse
cholesterol transport (20). Vitamin D also increases the lipolytic activity of heparin and
reduces VLDL-cholesterol synthesis (18).
In our study, the positive effect of vitamin D supplementation on total cholesterol
and triglycerides was observed only in the 6000 IU group despite both groups reaching
similar serum vitamin D levels. It may be that sufficient vitamin D status was achieved
sooner in the 6000 IU/group. Therefore, participants were exposed to sufficient vitamin D
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for a longer period of time. The half-life of vitamin D 3 is about 2 months. Therefore,
maintaining a plateau of sufficient 25(OH)D levels for more than 20 weeks is needed in
order to see improvements on tissues not related to calcium metabolism (21).
Our study has several strengths. First, to our knowledge this is the first study that
analysed vitamin D supplementation effects on Hispanics and African Americans with
T2D. Second, the dosages used were large enough to raise serum vitamin D to normal
levels in a population that was insufficient at baseline. Third, analysis was adjusted for a
wide range of covariates related to vitamin D metabolism. Lastly, compliance in our
study was high with 94% for the 4000 IU group and 92% for the 6000 IU group without
any differences between groups. No adverse events were reported during the course of
the study.
Limitations of our study included. First, participants were not randomly
distributed among groups. Second, there was an imbalance in baseline characteristics for
BMI and HDL-cholesterol. Third, there was a difference in sample size between groups
which may have decreased the statistical power. Fourth, a longer duration of treatment
may be needed to see more drastic effects on lipid profile. Fifth, the number of African
American participants was not large enough to analyze data by ethnicity. Lastly, 64% and
68% of participants were taking lipid lowering medication in the 4000 IU and 6000 IU
groups, respectively. Medication use may mask the effect of vitamin D supplementation.
We tried to control for it by advising participants to keep their medication use constant
during the study. However, this panorama reflects common clinical practice among
patients with type 2 diabetes.

34

Finally, our results suggest that the positive effect of vitamin D supplementation
on lipid profile may be mediated by other cofactors related to vitamin D metabolism
among Hispanic and African American participants with type 2 diabetes. Longer, well
designed randomized clinical trials are needed to confirm these results.

Table 1. Baseline characteristics of participants prior to vitamin D repletion treatments
Characteristic

Treatment
4000 IU (n=50)
6000 IU (n=25)

P-value

25(OH)D (ng/ml)
22.25 ± 7.19
23.74 ± 5.09
0.302
FGP (mg/dl)
188.76 ± 87.19
168.16 ± 55.94
0.220
Age (years)
54.76 ± 8.56
54.17 ± 10.99
0.999
Gender (Female %)
48%
52%
0.809
Years with T2D
6.48 ± 5.18
5.48 ± 5.93
0.478
Smoking (yes %)
10%
28%
0.091
2
BMI (kg/m )
34.72 ± 6.98
30.74 ± 4.93
0.013
Total Cholesterol (mg/dl)
213.08 ± 42.30
193.88 ± 41.03
0.065
Triglycerides (mg/dl)
182.98 ± 110.11
201.44 ± 91.35
0.445
LDL cholesterol (mg/dl)
128.34 ± 40.54
115.56 ± 34.53
0.160
HDL cholesterol (mg/dl)
50.64 ± 12.20
42.44 ± 10.40
0.004
Vitamin D intake (IU/day) 316.82 ± 251.70
301.97 ± 225.49
0.797
Sun exposure score
20.06 ± 14.92
18.68 ± 15.52
0.715
Upper arm skin color
58.67 ± 9.54
62.09 ± 5.65
0.056
Forearm skin color
54.82 ± 8.51
54.37 ± 4.37
0.099
Lipid lowering meds
64%
68%
0.215
Continues variables are presented as mean ± SD and categorical variables as %.
25(OH)D: serum vitamin D, FPG: fasting plasma glucose, T2D: type 2 diabetes, BMI:
body mass index, LDL: low density lipoprotein, HDL: high density lipoprotein.
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Table 2. Group comparisons of metabolic parameters at different time points without
adjusting for covariates
4000 IU (n=50)
6000 IU (n=25)
25(OH)D (ng/ml)
Baseline
22.25 ± 7.19
23.74 ± 5.09
3 months
37.34 ± 12.31*
43.20 ± 15.94*
*
6 months
37.99 ± 13.22
40.62 ± 19.39*
P-value groups = 0.225
P-value time = 0.006
P-value interaction = 0.238
Total Cholesterol (mg/dl)
Baseline
213.08 ± 42.30
193.88 ± 41.03
3 months
209.26 ± 43.62
184.68 ± 50.89
6 months
199.84 ± 32.79
180.48 ± 27.53*
P-value groups = 0.027
P-value time = 0.044
P-value interaction = 0.653
Triglycerides (mg/dl)
Baseline
182.98 ± 110.11
201.44 ± 91.35
3 months
174.62 ± 109.83
192.20 ± 94.49
6 months
187.08 ± 151.26
172.92 ± 76.87*
P-value groups = 0.221
P-value time = 0.117
P-value interaction = 0.227
LDL Cholesterol
Baseline
128.34 ± 40.54
115.56 ± 34.53
3 months
125.88 ± 40.90
120.00 ± 35.37
6 months
120.76 ± 30.35
121.96 ± 40.60
P-value groups = 0.542
P-value time = 0.685
P-value interaction = 0.354
HDL Cholesterol
Baseline
50.64 ± 12.20
42.44 ± 10.40
3 months
48.92 ± 11.12
42.12 ± 12.35
6 months
46.98 ± 10.37
42.12 ± 12.76
P-value groups = 0.072
P-value time = 0.214
P-value interaction = 0.351
Data represented by mean ± standard error. * Represents significant differences from
baseline. Level of significance is at P<0.05. 25(OH)D: serum vitamin D, LDL: low
density lipoprotein, HDL: high density lipoprotein.
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Table 3. Group comparisons of metabolic parameters at different time points adjusting
for covariates
4000 IU (n=50)
6000 IU (n=25)
25(OH)D (ng/ml)
Baseline
22.25 ± 7.19
23.74 ± 5.09
3 months
37.34 ± 12.31*
43.20 ± 15.94*
*
6 months
37.99 ± 13.22
40.62 ± 19.39*
P-value groups = 0.232
P-value time = 0.019
P-value interaction = 0.352
Total Cholesterol (mg/dl)
Baseline
213.08 ± 42.30
193.88 ± 41.03
3 months
209.26 ± 43.62
184.68 ± 50.89
6 months
199.84 ± 32.79
180.48 ± 27.53
P-value groups = 0.204
P-value time = 0.954
P-value interaction = 0.605
Triglycerides (mg/dl)
Baseline
182.98 ± 110.11
201.44 ± 91.35
3 months
174.62 ± 109.83
192.20 ± 94.49
6 months
187.08 ± 151.26
172.92 ± 76.87
P-value groups = 0.962
P-value time = 0.250
P-value interaction = 0.167
LDL Cholesterol
Baseline
128.34 ± 40.54
115.56 ± 34.53
3 months
125.88 ± 40.90
120.00 ± 35.37
6 months
120.76 ± 30.35
121.96 ± 40.60
P-value groups = 0.969
P-value time = 0.872
P-value interaction = 0.423
HDL Cholesterol
Baseline
50.64 ± 12.20
42.44 ± 10.40
3 months
48.92 ± 11.12
42.12 ± 12.35
6 months
46.98 ± 10.37
42.12 ± 12.76
P-value groups = 0.088
P-value time = 0.188
P-value interaction = 0.118
Data represented by mean ± standard error. * Represents significant differences from
baseline. Level of significance is at P<0.05. 25(OH)D: serum vitamin D, LDL: low
density lipoprotein, HDL: high density lipoprotein. Analysis was adjusted for age,
gender, years with diabetes, smoking, BMI, vitamin D intake, sun exposure score, fasting
plasma glucose, upper arm skin color, forearm skin color, and lipid lowering medication
use.
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CHAPTER III: THE EFFECT OF VITAMIN D SUPPLEMENTATION ON
GLUCOSE HOMEOSTASIS IN MINORITIES WITH TYPE 2 DIABETES

Introduction
Low levels of vitamin D are prevalent in the US. According to data from the
National Health and Nutrition Examination Surveys (NHANES) in 2001-2006, 33% of
the general US population had serum 25(OH)D below 50 nmol/L. In addition, low
vitamin D levels are common among minorities. For instance, 41% of African Americans
and 33% of Mexican Americans had serum 25(OH)D below 50 nmol/L compared to 18%
of non-Hispanic Whites (1).
Vitamin D is produced in the skin by the action of ultraviolet light. Vitamin D can
also be obtained from the diet with consumption of vegetable and animal products.
Vitamin D 3 needs to be activated by hydroxylation in the liver and kidney to form its
metabolically active form: 1,25(OH) 2 D 3 . This metabolite produces its effects by
activating the vitamin D receptor (VDR) in the cells (2).
With respect to diabetes, the VDRs are found in genes encoding proteins
important for beta cell function which may have some effect on glucose homeostasis. For
instance, vitamin D increases the calcium concentration in the cell which may translate
into better glucose uptake. Similarly, vitamin D has anti-inflammatory properties that
may reduce the chronic inflammation seen in T2D (3). Therefore, providing vitamin D to
individuals with T2D may have an effect on glucose homeostasis.
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In fact, several interventional studies providing vitamin D to participants at risk or
with T2D have been conducted with inconsistent results. Borissova et al (4) examined the
effect of vitamin D 3 supplementation on insulin resistance and insulin secretion in 10
patients with T2D. Seventeen age and gender-matched individuals without T2D served as
controls. The intervention group received 1332 IU of cholecalciferol daily for 1 month.
Fasting plasma insulin secretion increased significantly by 34.3%, however, the decrease
in insulin resistance was not significant. The small sample size and short duration of
treatment were the major limitations of this study. In similar studies, vitamin D
supplementation in men with T2D improved insulin secretion (5, 6). Inomata et al. (5)
provided 2ug/d (80 IU/day) of alphacalcidiol versus placebo to 14 Japanese males with
T2D, with mean age of 54.3±6.4 years for 3 weeks. The area under the oral glucose
tolerance test curve was used as a measure of insulin secretion. Results showed improved
insulin secretion. Limitations of this study were lack of measure of plasma vitamin D
concentrations and the small sample size. Similarly, Orwoll et al. (6) provided 1ug/d (40
IU/d) of 1,25(OH) 2 D versus placebo to 35 adults recently diagnosed with T2D (within 3
years) for 14 days, with mean age of 61±4.3 years. Insulin secretion was determined
from the area under the curve for the glucose tolerance test after a meal challenge. A
tendency for better insulin secretion was observed. The main limitations of this study
were the short duration of the intervention and the lack of assessment of serum vitamin D
post-intervention.
In contrast, Jorde et al. (7) provided 40,000 IU per week versus placebo to 32
participants with T2D for 6 months. No significant change on insulin, fasting plasma
glucose or A1C was noted. Participants in this study were not vitamin D insufficient,
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suggesting that vitamin D supplementation may have no effect on participants that are not
vitamin D insufficient. Conflicting reports may be a consequence of different
characteristics of the populations, inadequate dosages, different forms of vitamin D
supplements used, short duration of the studies, different outcome variables, and lack of
control of serum vitamin D levels pre and post intervention.
The vast majority of these studies have been conducted in non-Hispanic White
populations. Prevalence of hypovitaminosis D however, is found to be higher in Blacks
and Hispanics as compared to Whites (8-10). Since minorities such as African Americans
and Hispanics have higher risk of both T2D and vitamin D deficiency as compared to
Caucasians (11), it is important to determine the effect of vitamin D supplementation in
this high risk population.
The aim of the present study was to determine the effect of supplemental vitamin
D intake (4000 IU or 6000 IU of Cholecalciferol daily for 6 months) on fasting plasma
glucose, fasting insulin, and A1C in a sample of African-Americans and Hispanics with
T2D and vitamin D insufficiency (25(OH)D<30 ng/ml), 30-70 years of age, and living in
South Florida.

Methods
Subject Recruitment
An intervention study to assess the effects of vitamin D supplementation (4000
IU/day and 6000 IU/day) over six months on cardiovascular disease markers among a
sample of African Americans and Hispanics with T2D was conducted. The present study
analyzed the data collected at screening (serum 25(OH)D), baseline (fasting plasma
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glucose, fasting insulin, and A1C), 3 months (serum 25(OH)D, fasting plasma glucose,
fasting insulin, and A1C), and 6 months (serum 25(OH)D, fasting plasma glucose, fasting
insulin, and A1C).
The study consisted of two phases: phase one included the screening of
individuals, phase two included the recruitment of individuals who met inclusion criteria
and beginning of the vitamin D intervention trial. Inclusion criteria were vitamin D
insufficiency (25(OH)D< 30 ng/ml), 30-70 years of age, African American or Hispanic
with confirmed T2D. Exclusion criteria were taking vitamin D supplements other than
standard daily multivitamin formula, being pregnant or lactating, having thyroid, hepatic,
renal dysfunction, cancer, HIV, or major psychiatric disorders.
Flyers explaining the purpose of the study, inclusion/exclusion criteria and the
investigators’ emails and phone numbers were distributed in highly visited community
areas such as churches, supermarkets, and clinics. Two clinics were visited every week
for recruitment purposes: Borinquen Health Care Center and Clinical Care Medical
Center. When volunteer participants called the investigators back, purposes of the study
were explained and specific questions were asked to assure compliance with inclusion
criteria. All qualified participants were invited to take part in a morning session at the
Human Nutrition Laboratory at Florida International University (FIU) for fasting blood
sampling to screen for vitamin D insufficiency. The study was approved by IRB at FIU.
All participants were asked to sign an informed consent form previous to screening data
collection. Only participants with confirmed T2D diagnosis by a physician were eligible
for the study. All participants were screened for vitamin D insufficiency in phase one.
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They were contacted either to continue in the study or to inform them that they were
disqualified based on their vitamin D levels.
Participants in both groups were required to take either 4000 IU or 6000 IU of
vitamin D (Cholecalciferol) per day given in the form of a pill in a single daily dose.
Compliance was determined by returned pill count at follow ups. When less than 80% of
the pills were taken, the subject was classified as non-compliant. Adverse events were
recorded at each visit. Each participant was seen 4 times; at screening, baseline, 3
months, and 6 months. Serum 25(OH)D was measured at screening, 3 months, and 6
months. Fasting plasma glucose, fasting insulin, and A1C were measured at baseline, 3
months, and 6 months visits. The time spam between screening and baseline was one
week.
Total study lasted for 25 weeks for each participant from screening to final
assessment. The study started in June 2011 and was completed on September 2013.
Ninety two participants were screened. Seventy five qualified for the intervention (n=50
for 4000 IU/day treatment and n=25 for 6000 IU/day treatment). Three participants
qualified for the study based on their vitamin D status but did not attend the 3 month and
6 month follow ups (all in the 4000 IU group). Eight participants attended the 3 month
but not the 6 month follow up (5 in the 4000 IU and 3 in the 6000 IU group,
respectively). Five participants completed the study but were non-compliant (3 in the
4000 IU and 2 in the 6000 IU treatment, respectively). Since an intent to treat approach
was followed, all 75 participants were included in the present study.

Blood Collection
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Venous blood (15 ml) was collected from each subject by a certified phlebotomist
using standard laboratory methods at each study point. After coagulation, blood was
centrifuged at 2500 RPM for 30 minutes. The plasma glucose concentration was
measured by hexokinase enzymatic method. A1C was measured by the DCA2000+
system (Bayer Corporation, Diagnostics Division, N.Y.) using the monoclonal antibody
method. Insulin in fasting blood was determined by radioimmunoassay using an insulinspecific kit (Linco Research Inc., St. Charles, MO). Serum vitamin D concentrations
were measured with an enzyme-immunoassay kit by absorbance (Immunodiagnostic
Systems Scottsdale, AZ). Vitamin D values were tested at screening, 3 month and 6
month visits. Fasting plasma glucose, fasting insulin, and A1C were tested at baseline, 3
month, and 6 month visits.

Socio-demographic Questionnaire
Participants were asked to fill out standard questionnaires on site. Trained
interviewers bilingual in English and Spanish administered the questionnaires in the
language of preference of the participants. Data were collected using a sociodemographic questionnaire which includes questions related to gender, age, education,
years with diabetes, smoking, and medications at baseline.

Anthropometric Measurements
Height and weight were measured using a SECA clinical balance scale (Seca
Corp, Columbia, MD). Body mass index (BMI) was calculated as weight in kg/height in
m2. BMI was calculated for baseline, 3 month, and 6 month visits. Only baseline values
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were used for the analysis due to the lack of significant changes in BMI at 3 months and
6 months.

Sun Exposure Questionnaire
The sun exposure questionnaire developed by Hanwell et al. (12) was applied
following the original rubric. Time spent outdoors during the previous week (0≤5
minutes, 1=5-30 minutes and 2= >30 min) was self-reported. Four options for skin
exposed while outdoors were offered (1=face and hands, 2=face, hands and arms, 3=face,
hands and legs and 4=bathing suit). The daily sun exposure score for each day was
calculated by multiplying the time spent outdoors score times the skin exposed while
outdoors score. The scale for each day ranged from 0 to 8. The weekly sun exposure was
calculated by adding the daily scores (min =0, max=56). The questionnaire was
administered at baseline, 3 months, and 6 months, but because it did not change
significantly, only baseline values were used in the analysis. Since the sun is the main
source of vitamin D, baseline sun exposure may have an effect on our final outcomes.
Therefore, analysis was adjusted for sun exposure.

Skin Color
In order to have an objective measure of sun exposure, skin color was determined
by reflectance colorimetry using the SmartProbe 400 (IMS Inc. USA). This instrument
uses the International Commission on Illumination Scale which ranges from 0 (black) to
100 (white) for skin color. Two readings at each measurement site for each participant
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were taken: two on the dorsal aspect of the wrist of the right hand (area most exposed to
sun), two on the inside of the right upper arm (area less exposed to the sun). The mean
values of the two readings at each measurement site were used for analysis. Data were
collected at baseline, 3 months, and 6 months, but because it did not change significantly,
only baseline values were used in the present analysis. Since participants with darker skin
color tend to have lower levels of serum 25(OH)D, skin color may have an effect on
glucose homeostasis. Therefore, analysis of the effect of vitamin D supplementation on
lipid panel was adjusted for skin color.

Assessment of Dietary Intake
Dietary intake was determined using the long food frequency questionnaire (FFQ)
developed by Walter Willett (13). This FFQ has been validated in different ethnic groups
and, also, specifically in Cuban-Americans in South Florida (14). Participants selfreported the average consumption of specific amount of foods over the past 12 months.
Frequencies ranged from “never” to “six or more servings per day”. The FFQ also
assessed the frequency use of multivitamin/mineral supplements, salt, sugar, alcohol and
vitamin D intake. The questionnaire was administered at baseline.

Statistical analysis
Descriptive statistics were used for baseline characteristics. Numerical normally
distributed data and categorical data were compared using independent t-test and ChiSquared test, respectively. Intent to treat analyses was used to analyze the effect of
vitamin D on the outcome variables.
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Main variables of the study were: fasting plasma glucose, A1C, and fasting
insulin. All the variables were input as continuous in the analysis. Control variables
included: BMI, gender, age, smoking, years with diabetes, sun exposure score, vitamin D
intake, and skin color.
Mixed model was used to compare treatment effects (4000 IU vs. 6000 IU) on the
outcome variables. Bonferroni multiple comparison tests was used to detect significant
changes from baseline, 3 months, and 6 months on the outcome variables with and
without adjusting for age, gender, years with diabetes, smoking, BMI, vitamin D intake,
sun exposure score, upper arm skin color, and forearm skin color. Significance was set at
p<0.05 and all analyses were two sided. Statistical analysis was conducted using SPSS
18.0 (Chicago).

Results
Groups were similar in all baseline characteristics except for BMI (34.72 ± 6.98
kg/m2 vs. 30.74 ± 4.93 kg/m2, P=0.013 for 4000 IU and 6000 IU; respectively) (Table 1).
There was no significant difference between groups regarding serum 25(OH)D
(P=0.225). However, significant improvements in serum 25(OH)D levels were seen from
baseline to 3 month and 6 months, respectively in both treatments (from 22.25 ± 7.19 to
37.34 ± 12.31 and 37.99 ± 13.22, P<0.05 in the 4000 IU group; from 23.74 ± 5.09 to
43.20 ± 15.94 and 40.62 ± 19.39, P<0.05 in the 6000 IU group) (Table 2).
Differences between 3 months and 6 months levels for serum 25(OH)D were not
significant in both treatments (P>0.05). In the 6000 IU group, the value showed a nonsignificant decline at 6 months compare to the 3 months follow up.
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A decreasing trend was observed for fasting plasma glucose in the 4000 IU group
and for A1C in the 6000 IU group. However, no significant changes were observed for
fasting plasma glucose, insulin or A1C between groups and within groups both in the
unadjusted and adjusted models (Table 2 and Table 3). Similarly, interaction values were
not-significant (Table 2 and Table 3).
Adherence defined as consumption of more than 80% of supplied vitamin D pills
was 94% for the 4000 IU group and 92% for the 6000 IU group without any differences
between groups. No adverse events were reported during the course of the study.

Discussion
Low serum vitamin D levels are common among participants with type 2
diabetes. However, it is still uncertain if there is a cause and effect association between
these two conditions or if low vitamin D levels are just a marker of worse health status.
Impaired β cell function and insulin resistance are the two factors that lead to
development of type 2 diabetes. Vitamin D deficiency decreased the ability of β cells to
secrete insulin, while vitamin D repletion restored insulin secretion in vitro studies (15).
The direct effect of vitamin D in β cells may be caused by the binding of the active
metabolite 1,25 dihydroxyvitamin D to the vitamin D receptor site on these cells (16).
The indirect effect of vitamin D in insulin secretion may be due the regulation of calcium,
since insulin secretion is a calcium-dependent process (17). Insulin sensitivity may also
be improved in peripheral cells by increasing the expression of insulin receptors and by
increasing the calcium concentration (3). In order to prevent type 2 diabetes,
interventions that preserve β cell function are desired.
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Studies regarding the effect of vitamin D supplementation for participants at risk
or with type 2 diabetes had provided conflicting results. Some intervention studies
conducted in small samples and for short duration have shown improvements in insulin
secretion, but not insulin sensitivity (3,18). Studies with positive results were conducted
in participants with a recent diagnosis of type 2 diabetes (< 3 years) or at risk of type 2
diabetes. Pittas et al. (18), found that 700 IU/day of vitamin D 3 combined with calcium
improved insulin resistance in participants with impaired glucose tolerance. Mitri et al.
(3), found that 2000 IU/day of vitamin D 3 for 16 weeks improved the disposition index
and insulin secretion in participants at risk of type 2 diabetes. In addition, even though,
no significant change was seen in A1C levels, there was a trend toward and attenuation
on the rise of this marker, which occurs over time in the natural history of pre-diabetes.
Intervention studies conducted with participants with established type 2 diabetes
(> 3 years) had found negative results. Jorde et al (7) provided 40,000 IU per week versus
placebo to 32 participants with T2D for 6 months. No significant change in insulin,
fasting plasma glucose or A1C was noted. A meta-analysis of 15 randomized clinical
trials reported that a reduction in fasting plasma glucose and insulin resistance was
observed only in participants with impaired glucose tolerance, but no effect was observed
in participants with type 2 diabetes after vitamin D supplementation (19).
Our results did not support the hypothesis that vitamin D supplementation may
improve glucose homeostasis in patients with established type 2 diabetes. Our
participants had 6.48 ± 5.18 and 5.48 ± 5.93 years with type 2 diabetes for the 4000 IU
and 6000 IU groups, respectively. This may indicate that vitamin D supplementation have
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no effect on glucose homeostasis once beta cell function have passed a certain point of
deterioration.
In fact, Alkharfy et al. (20), conducted a study to determine the effect of 2000
IU/day of Cholecalciferol supplementation for 12 months among participants on diet,
insulin, or oral hypoglycemic agents compared with a healthy control group. No
improvements on glucose homeostasis were found in any of the groups. However,
significant reduction in triglycerides and total cholesterol were observed in the insulin +
vitamin D and oral hypoglycemic agents + vitamin D groups. According to a similar
study, vitamin D seems to have a better effect on lipid panel and not on markers of
glycemic control in patients with type 2 diabetes (21).
Our study had sufficient power to find changes in fasting plasma glucose, fasting
insulin, and A1C. The vitamin D supplement dosages provided were high enough to
achieve serum 25(OH)D>30 ng/ml which is the level recommended for optimum health
(22). However, this recommendation (serum 25(OH)D>30 ng/ml) was based on
observational studies and evidence from intervention studies about the optimum vitamin
D level for adequate glucose homeostasis is lacking. Another strong point of our study
was that individuals did not change medication, vitamin D intake, BMI, smoking or sun
exposure habits during the course of the study and analysis was adjusted for those
variables. In addition, compliance in our study was high with 94% for the 4000 IU group
and 92% for the 6000 IU group without any differences between groups. No adverse
events were reported during the course of the study.
In contrast, a factor that may explain the negative results in our study may be that
our sample was categorized as obese according to their BMI. Since vitamin D is
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sequestered in the fat tissue and not metabolically active in obese patients (23), it may be
possible that a higher dosage or a longer duration of treatment is needed to see changes in
glucose homeostasis markers in obese participants with type 2 diabetes.
Similarly, all our participants were vitamin D deficient at baseline. Therefore, it
may be possible that after vitamin D repletion, other functions related to vitamin D are
improved first and β cell restoration was not the priority. Since our sample did not have
enough variability regarding baseline vitamin D levels, a post hoc analysis adjusting for
baseline vitamin D levels to see if the ones who started with higher serum vitamin D
levels improved the most did not find any significant results either.
A trend for a decline in fasting plasma glucose was observed in the 4000 IU
group. However, since no improvement was observed in A1C, a marker of long term
glycemic control, changes in fasting plasma glucose are of limited significance in this
population with established type 2 diabetes.
Limitations of our study include the use of a convenience sample without
randomization, thus our results are not generalizable, the small number of African
American participants which did not allow us to analyze the data by ethnicity, and the
inclusion of only participants with vitamin D deficiency which decreased the external
validity of the study.
In conclusion, improvements in glucose homeostasis were not observed after 6
months of vitamin D 3 supplementation among Hispanics and African American
participants with type 2 diabetes. The main objective of glycemic control in patients with
type 2 diabetes is to prevent microvascular and macrovascular complications. The use of
surrogate measures like fasting plasma glucose, insulin resistance, and A1C are of
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practical clinical significance but not ideal for research purposes. Longer and larger
studies supplementing vitamin D to participants with type 2 diabetes that focus on
microvascular and macrovascular complications, instead of surrogate measures, are
needed to confirm our results.

Table 1. Baseline characteristics of participants prior to vitamin D repletion treatments
Characteristic

Treatment
4000 IU (n=50)
6000 IU (n=25)

P-value

25(OH)D (ng/ml)
22.25 ± 7.19
23.74 ± 5.09
0.302
FGP (mg/dl)
188.76 ± 87.19
168.16 ± 55.94
0.220
Age (years)
54.76 ± 8.56
54.17 ± 10.99
0.999
Gender (Female %)
48%
52%
0.809
Years with T2D
6.48 ± 5.18
5.48 ± 5.93
0.478
Smoking (yes %)
10%
28%
0.091
BMI (kg/m2)
34.72 ± 6.98
30.74 ± 4.93
0.013
A1C (%)
8.25 ± 2.40
8.26 ± 1.92
0.981
Insulin (µU/ml)
12.86 ± 12.82
12.13±7.08
0.753
Vitamin D intake (IU/day) 316.82 ± 251.70
301.97 ± 225.49
0.797
Sun exposure score
20.06 ± 14.92
18.68 ± 15.52
0.715
Upper arm skin color
58.67 ± 9.54
62.09 ± 5.65
0.056
Forearm skin color
54.82 ± 8.51
54.37 ± 4.37
0.099
Continues variables are presented as mean ± SD and categorical variables as %.
25(OH)D: serum vitamin D, FPG: fasting plasma glucose, T2D: type 2 diabetes, BMI:
body mass index, A1C: glycated hemoglobin.
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Table 2. Group comparisons of metabolic parameters at different time points without
adjusting for covariates

25(OH)D (ng/ml)
Baseline
3 months
6 months
P-value groups = 0.225
FPG (mg/dl)
Baseline
3 months
6 months
P-value groups = 0.321
Insulin (µU/ml)
Baseline
3 months
6 months
P-value groups = 0.748
A1C (%)
Baseline
3 months
6 months
P-value groups = 0.198

4000 IU (n=50)

6000 IU (n=25)

22.25 ± 7.19
37.34 ± 12.31*
37.99 ± 13.22*
P-value time = 0.006

23.74 ± 5.09
43.20 ± 15.94*
40.62 ± 19.39*
P-value interaction = 0.238

188.76 ± 87.19
182.14 ± 73.34
173.16 ± 73.54
P-value time = 0.265

168.16 ± 55.94
176.56 ± 59.68
160.96 ± 63.64
P-value interaction = 0.814

12.86 ± 12.82
11.08 ± 7.47
11.53 ± 7.84
P-value time = 0.390

12.13 ± 7.08
13.08 ± 7.25
12.20 ± 7.33
P-value interaction = 0.412

8.25 ± 2.40
8.32 ± 2.17
8.25 ± 2.14
P-value time = 0.402

8.26 ± 1.92
8.08 ± 1.63
8.05 ± 1.80
P-value interaction = 0.306

Data represented by mean ± standard error. * Represents significant differences from
baseline. Level of significance is at P<0.05. 25(OH)D: serum vitamin D, FPG: fasting
plasma glucose, A1C: glycated hemoglobin.
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Table 3. Group comparisons of metabolic parameters at different time points adjusting
for covariates

25(OH)D (ng/ml)
Baseline
3 months
6 months
P-value groups = 0.232
FPG (mg/dl)
Baseline
3 months
6 months
P-value groups = 0.439
Insulin (µU/ml)
Baseline
3 months
6 months
P-value groups = 0.859
A1C (%)
Baseline
3 months
6 months
P-value groups = 0.213

4000 IU (n=50)

6000 IU (n=25)

22.25 ± 7.19
37.34 ± 12.31*
37.99 ± 13.22*
P-value time = 0.019

23.74 ± 5.09
43.20 ± 15.94*
40.62 ± 19.39*
P-value interaction = 0.352

188.76 ± 87.19
182.14 ± 73.34
173.16 ± 73.54
P-value time = 0.311

168.16 ± 55.94
176.56 ± 59.68
160.96 ± 63.64
P-value interaction = 0.949

12.86 ± 12.82
11.08 ± 7.47
11.53 ± 7.84
P-value time = 0.475

12.13 ± 7.08
13.08 ± 7.25
12.20 ± 7.33
P-value interaction = 0.490

8.25 ± 2.40
8.32 ± 2.17
8.25 ± 2.14
P-value time = 0.417

8.26 ± 1.92
8.08 ± 1.63
8.05 ± 1.80
P-value interaction = 0.329

Data represented by mean ± standard error. * Represents significant differences from
baseline. Level of significance is at P<0.05. 25(OH)D: serum vitamin D, FPG: fasting
plasma glucose, A1C: glycated hemoglobin. Analysis was adjusted for age, gender, years
with diabetes, smoking, BMI, vitamin D intake, sun exposure score, upper arm skin
color, forearm skin color.
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CHAPTER IV: VITAMIN D REPLETION IN MINORITIES WITH TYPE 2
DIABETES AND COEXISTENT VITAMIN D INSUFFICIENCY

Introduction
Low levels of vitamin D are prevalent in the US (1). According to data from the
National Health and Nutrition Examination Surveys (NHANES) in 2001-2006, 33% of
the general US population had serum 25(OH)D below 50 nmol/L. In addition, low
vitamin D levels are especially common among minorities. For instance, 41% of African
Americans and 33% of Mexican Americans had serum 25(OH)D below 50 nmol/L
compared to 18% of non-Hispanic Whites (1).
Poor vitamin D status has been found in participants at risk or with type 2
diabetes (T2D), however, the nature of this relationship is not clear (2, 3). Similarly, a
negative association between vitamin D levels and insulin resistance has been reported in
a large sample representative of the US adult population and in participants at risk for
T2D (3, 4). According to these results, vitamin D levels are positively associated with
insulin sensitivity and negatively associated with insulin resistance. The findings further
suggest that vitamin D repletion would be of benefit to those with or at risk for diabetes.
Protocols for correction of vitamin D insufficiency in patients with cystic fibrosis,
chronic kidney disease, hyperparathyroidism, osteoporosis and pregnancy have been
published (5-9). However, there is no standard method developed for the repletion of
vitamin D insufficiency in participants with T2D.
Some regimens to improve the vitamin D status in participants with T2D have
been reported. For instance, Borissova et al (10) examined the effect of vitamin D 3
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supplementation on insulin resistance and insulin secretion in 10 patients with T2D. The
intervention group received 1332 IU of cholecalciferol daily for 1 month. Inomata et al.
(11) provided 2ug/d (80 IU/day) of alphacalcidiol versus placebo to 14 Japanese males
with T2D for 3 weeks and evaluated improvements in insulin secretion. However, this
study did not measure plasma vitamin D concentrations. Similarly, Orwoll et al. (12)
provided 1ug/d (40 IU/d) of 1,25(OH) 2 D versus placebo to 35 adults (mean age of 61
years old) with recently diagnosed T2D (within 3 years) for 14 days. A tendency for
better insulin secretion was observed. Main limitations of this study were the short
duration of the intervention and the lack of assessment of serum vitamin D postintervention. Persons with T2D and low serum 25(OH)D had improvements in glycemic
control with 3000 IU of vitamin D 3 for 6 and 9 months (13). None of these studies have
specifically evaluated the effectiveness of vitamin D supplementation regimens on
vitamin D repletion.
Recently, the Endocrine Society announced new clinical practice guidelines of
standard care for vitamin D supplementation for vitamin D insufficient populations
(1500-2000 IU daily for ages 19-70) to achieve sufficiency (25(OH)D >30 ng/ml) and
recommended an upper limit of 4000 IU/day as the threshold for safety in healthy
individuals. In addition, all adults who are vitamin D deficient (25(OH)D < 20 ng/ml) are
recommended to supplement with 6000 IU/d of vitamin D 3 until sufficiency is reached,
followed by a maintenance therapy of 2000 IU/d. In obese patients, and patients taking
medications that interfere with vitamin D metabolism, the suggested therapy is to
supplement with 6000-10000 IU/d of vitamin D 3 until sufficiency is reached, followed by
a maintenance therapy of 3000-6000 IU/d (14). Optimal vitamin D supplementation
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required for participants with T2D, and individuals with dark skin color who are also
insufficient in vitamin D has not been determined. Therefore, it is important to test the
efficacy of the new standard of care in African Americans and Hispanics with T2D or if
higher dosages are needed. However, there is concern that vitamin D repletion regimens
may produce toxicity. Serum 25(OH)D levels > 150 ng/ml have been used as the
threshold for toxicity (15).
The objective of the present study was to evaluate the efficacy and safety of two
vitamin D repletion regimens: 4000 IU and 6000 IU of Cholecalciferol daily for 6 months
in African Americans and Hispanics with T2D while monitoring serum vitamin D levels
for toxicity.

Methods
Participants
An intervention study to assess the effects of vitamin D supplementation (4000
IU/day and 6000 IU/day) over six months on cardiovascular disease markers among a
sample of African Americans and Hispanics with T2D was conducted. The present study
analyzed the data collected at screening, 3 months, and 6 months.
The study consisted of two phases: phase one included the screening of
individuals, phase two included the recruitment of individuals who met inclusion criteria
and beginning of the vitamin D intervention trial. The inclusion criteria were vitamin D
insufficiency (25(OH)D < 30 ng/ml), 30-70 years of age, African American or Hispanic
with confirmed T2D. Exclusion criteria were taking vitamin D supplements other than
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standard daily multivitamin formula, pregnant or lactating, having thyroid, hepatic, renal
dysfunction, cancer, HIV, and major psychiatric disorders.
Flyers explaining the purpose of the study, inclusion/exclusion criteria and
containing investigators’ emails and phone numbers were distributed in highly visited
community areas such as churches, supermarkets, and clinics. Two clinics were visited
every week for recruitment purposes: Borinquen Health Care Center and Clinical Care
Medical Center. When participants called the investigators, purposes of the study were
explained and specific questions were asked to assure compliance with inclusion criteria.
All qualified participants were invited to participate in a morning session at Human
Nutrition Laboratory at Florida International University (FIU) for fasting blood sampling
to screen for vitamin D insufficiency. All participants were asked to sign an informed
consent form previous to screening data collection and to provide contact number and
address of their physician, as well as their own contact information. Only participants
with T2D diagnosis confirmed by a physician were eligible to participate in the study.
The study was approved by IRB at FIU.
Participants in both groups were required to take either 4000 IU or 6000 IU of
vitamin D (Cholecalciferol) per day given in the form of a pill in a single daily dose.
Compliance was determined by pill count. When less than 80% of the pills were taken,
the subject was classified as non-compliant. Adverse events were recorded at each visit.
Each participant was seen 4 times; at screening, baseline, 3 months, and 6 months.
Parathyroid hormone (PTH) and serum 25(OH)D were measured at screening, 3 months,
and 6 months. Total study lasted for 25 weeks for each participant from screening to final
assessment. The study started in June 2011 and was completed on September 2013.
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Ninety two participants were screened. Seventy five qualified for the intervention (n=50
for 4000 IU/day treatment and n=25 for 6000 IU/day treatment). Three participants
qualified for the study based on their vitamin D status but did not attend the 3 month and
6 month follow ups (all in the 4000 IU group). Eight participants attended the 3 month
but not the 6 month follow up (5 in the 4000 IU and 3 in the 6000 IU group,
respectively). Five participants completed the study but were non-compliant (3 in the
4000 IU and 2 in the 6000 IU treatment, respectively). Since an intent to treat approach
was followed, all 75 participants were included in the present study.

Blood Collection
Venous blood (15 ml) was collected from each subject by a certified phlebotomist
using standard laboratory methods at each study point. After coagulation, blood was
centrifuged at 2500 RPM for 30 minutes. Glycated hemoglobin (A1C) was measured by
the DCA2000+ system (Bayer Corporation, Diagnostics Division, N.Y., U.S.) using the
monoclonal antibody method. Serum vitamin D concentrations were measured with an
enzyme-immunoassay kit by absorbance (Immunodiagnostic Systems Scottsdale, A.Z.,
U.S.). Color intensity developed was inversely proportional to the concentration of
25(OH)D. Parathyroid hormone was determined by an electrochemiluminescence
immunoassay (E170, Roche, Basel, Switzerland).

Socio-demographic Questionnaire
Participants were asked to fill out standard questionnaires on site. Trained
interviewers bilingual in English and Spanish administered the questionnaires in the
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language of preference of the participants. Data were collected using a sociodemographic questionnaire which included questions related to gender, age, years with
diabetes, and smoking.

Anthropometric Measurements
Height and weight were measured using a SECA clinical balance scale (Seca
Corp, Columbia, MD). Body mass index (BMI) was calculated as weight in kg/height in
m2.

Statistical Analysis
The descriptive statistics for continuous variables are presented as mean ± SD and
proportions for categorical variables. Baseline continues variables and categorical
variables among participants in the 4000 IU and 6000 IU treatments were compared
using independent samples t test and Chi Square test, respectively. The Student’s t test for
paired samples was used to test changes in serum 25(OH)D and PTH over 3 and 6
months. Results were confirmed running a standard mixed-models approach to repeated
measures. A multiple linear regression model was run to test the association among
serum 25(OH)D changes and PTH changes at 3 and 6 months for each treatment.
Significant models were adjusted for age, gender, BMI, years with T2D, smoking, and
A1C. The association between achieving sufficient vitamin D status and treatment was
tested with a logistic regression model. Vitamin D status (sufficient/insufficient) was
input as the dependent variable and treatment (4000 IU and 6000 IU) as the independent
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variables. All analyses were performed using SPSS version 19 (Chicago, IL, US). A pvalue of <.05 was considered significant.

Results
Both treatment groups were similar at baseline in serum 25(OH)D, PTH, age,
gender distribution, years with T2D, smoking, and A1C levels. However, participants in
the 4000 IU group showed a higher BMI compared to participants in the 6000 IU group
at baseline (34.72 ± 6.98 vs. 30.74 ± 4.93 kg/m2, P=0.013) (Table 1).
Serum 25(OH)D increased significantly at 3 months in both treatments, from
22.25 ± 7.19 to 37.34 ± 12.31 ng/ml and from 23.74 ± 5.09 to 43.20 ± 15.94 ng/ml in the
4000 IU (P=0.001) and 6000 IU (P=0.001) groups, respectively (Table 2). The mean
increase between treatments was not significantly different at 3 months.
Similarly, serum 25(OH)D increased significantly at 6 months in both treatments,
from 22.25 ± 7.19 to 37.99 ± 13.22 ng/ml and from 23.74 ± 5.09 to 40.62 ± 19.39 ng/ml
in the 4000 IU (P=0.001) and 6000 IU (P=0.001) groups, respectively (Table 2). The
mean increase between treatments at 6 months was not significant.
In addition, serum 25(OH)D levels at 3 months and at 6 months were not
significantly different for both treatments, meaning that there was no additional benefit to
extending the treatment for 6 months at any dosage in terms of increasing serum
25(OH)D levels.
Parathyroid hormone levels decreased at 3 months and 6 months compared to
baseline. However, the change was not significant for any time period (Table 2). In
addition, there was a non significant increase in PTH at 6 months compared to 3 months.
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The association between serum 25(OH)D change and PTH change was only significant at
3 and 6 months for the 4000 IU treatment (β=-0.223, P=0.012 and β=-0.235, P=0.016;
respectively). This association held its significance even when the model was adjusted for
covariates at 3 months and 6 months (β=-0.176, P=0.045 and β=-0.209, P=0.039;
respectively). Keeping other covariates constant, an increase of 1 unit in serum 25(OH)D
decreased PTH by 0.176 units at 3 months (Table 3). Similarly, keeping other covariates
constant, an increase of 1 unit in serum 25(OH)D decreased PTH by 0.209 units at 6
months (Table 4). The fully adjusted model explained 29.3% of the change in PTH at 3
months and 26.4% at 6 months.
The association between vitamin D status (insufficient/sufficient) and treatment
(4000 IU and 6000 IU) was not significant. None of the participants with either dose had
showed serum 25(OH)D > 150 ng/ml and no adverse events were reported during the
study. Re-analysis of the data after excluding the participants that dropped out of the
study after screening and at 3 months, did not alter the results.

Discussion
Treatments with 4000 IU/day and 6000 IU/day increased serum 25(OH)D levels
significantly at 3 months and 6 months compared to baseline values. The proportion of
participants achieving sufficient serum 25(OH)D levels was 68% at 3 months and 70% at
6 months for 4000 IU; and 72% at 3 months and 68% at 6 months for 6000 IU.
These results support the notion that 4000 IU/day for 3 months is an adequate
dosage to replenish vitamin D in Hispanics and African Americans with T2D. Additional
treatment for 3 extra months or a higher dosage of 6000 IU/day did not change serum
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25(OH)D levels significantly. According to these data, a physiological plateau is reached
at 3 months with the use of the 4000 IU/day regimen. However, the sample size for the
6000 IU group was small (n=25). In addition, the inclusion of the non-compliant
participants (n=2) and the dropouts (n=3) in the intent to treat analysis for the 6000 IU
group may have pulled the p-value to the non-significant side. According to Pepper et al.
(15), a much higher serum 25(OH) needs to be achieved to see changes in metabolic
markers not related to bone turn over or calcium metabolism. Therefore, it remains to be
seen if this serum 25(OH)D may have an effect on cardiovascular risk in this particular
sample of Hispanics and African Americans with T2D.
The Endocrine Society recommends that vitamin D insufficient adults consume
1500-2000 IU/day with an upper limit of 4000 IU/day as the limit for safety (14).
However, this recommendation is for healthy individuals. Since participants with T2D,
African Americans, and Hispanics tend to have a higher incidence of vitamin D
deficiency due to darker skin color and higher metabolic demands, it is assumed that a
higher dosage is needed to achieve sufficiency in this particular population (1-3).
However, no standard vitamin D repletion treatment has been developed for participants
with T2D and darker skin color.
Our results support the regimens followed for other metabolic disorders.
Malabanan et al. (16) showed that 50000 IU once a week per 8 weeks of ergocalciferol
improved vitamin D status in participants with osteoporosis. Sixty percent of participants
achieved sufficient status at the end of the study. This proportion achieving sufficiency is
similar to the one achieved with the 4000 IU/day in the present study. Similarly, the
National Kidney Foundation has released guidelines for the repletion of vitamin D in
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participants with chronic kidney disease based on the level of insufficiency (<5 ng/ml, 5
to 15 ng/ml, 16 to 30 ng/ml). Participants in the category with the highest insufficiency
should have supplements with 50000 IU weekly of ergocalciferol for 12 weeks followed
by a monthly similar maintenance dose, 50000 IU weekly for 4 weeks and then monthly
for participants in the middle category, and 50000 IU monthly for participants in the
category with the lowest insufficiency (6).
These guidelines are based on ergocalciferol. However, in our study
cholecalciferol was provided. Studies have shown that cholecalciferol may be more
bioavailable than ergocalciferol (17-19). Therefore, plateau levels may be achieved faster
and maintained for longer time. In a study providing equal molar quantities of
cholecalciferol and ergocalciferol (4000 IU) for 14 days, participants in the
cholecalciferol group achieved 1.7 times higher serum 25(OH)D compared to the
ergocalciferol group (18). Similarly, Armas et al. (19), reported higher serum 25(OH)D
levels in patients taking cholecalciferol compared to ergocalciferol. Variation in the
binding of cholecalciferol and ergocalciferol to the vitamin D binding protein may
explain these results (17).
Regarding the relationship between serum 25(OH)D and dosage provided, Pepper
et al. (15) found a direct association. Participants receiving a total dose < 300000 IU of
ergocalciferol were 7 times more likely to remain vitamin D insufficient compared to
participants taking > 600000 IU. Following the same trend, participants receiving
between 300001 and 599999 IU of ergocalciferol were 3 times more likely to remain
vitamin D insufficient compared to participants taking > 600000 IU. In our study, the
relationship between dosage and insufficient status was not significant. This relation held
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even when participants who dropped out of the study were excluded from the analysis.
Therefore, there is no advantage in increasing the dosage to 6000 IU/day. It may be
possible that the use of cholecalciferol saturated the vitamin D receptors faster compared
to studies providing ergocalciferol.
Studies conducted in participants with T2D have assessed changes in metabolic
outcomes (insulin resistance, and insulin production) after vitamin D supplementations.
Comparing our results to those in the literature, however, is difficult because previous
studies did not enroll vitamin D insufficient participants or assess serum 25(OH)D values
before and after treatment (10-13).
Even though, changes in PTH were not significant, the relationship between
change in serum 25(OH)D and change in PTH was correlated for the 4000 IU group. The
fully adjusted model explained 29.3% of the change in PTH at 3 months and 26.4% at 6
months. Still a large proportion of the change in PTH was not explained by the model.
This finding suggests that to reduce bone turn over in this population other factors may
be more important than vitamin D alone. In fact, age was a significant factor that affected
PTH levels. These results support the notion that once vitamin D sufficiency is achieved,
PTH levels do not continue decreasing (15). Studies have demonstrated that PTH levels
achieve a plateau when serum 25(OH)D reaches a level of 30 to 32 ng/ml (20,21).
Regarding safety, studies have shown that dosages of 10000 IU/day of
Cholecalciferol did not produce toxicity when provided to insufficient participants (22).
In fact, none of the participants in our study reported any adverse events or achieved a
serum 25(OH)D > 150 ng/ml. Therefore, it seems that both treatments are safe to use
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among this particular population of Hispanics and African Americans with T2D for six
months.
Limitations of our study include the small sample size in the 6000 IU group and
the use of fixed time intervals. Therefore, the peak levels of serum 25(OH)D may have
been missed. In addition, since participants with T2D are prone to developing renal
disease, it may be possible that the conversion of Cholecalfierol to serum 25(OH)D may
have been impaired in participants at early stages of renal disease. Further studies in
participants that did not reach vitamin D sufficiency over the 6 months treatments are
needed in order to explain the possible causes.
In conclusion, repletion of vitamin D among Hispanics and African Americans
with T2D was successfully and safely achieved with a 4000 IU/day dose of
cholecalciferol for 3 months in most participants. The increase in treatment time or
dosage did not produce any significant difference in terms of achieving vitamin D
sufficient status. The effect of the change in vitamin D status on metabolic markers
should be evaluated in future studies to determine the optimal time of treatment for
patients with T2D.
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Table 1. Baseline characteristics of participants prior to vitamin D repletion treatments
Characteristic

Treatment
4000 IU (n=50)
6000 IU (n=25)

P-value

25(OH)D (ng/ml)
22.25 ± 7.19
23.74 ± 5.09
0.302
PTH (pg/ml)
38.60 ± 18.14
41.42 ± 17.77
0.523
Age (years)
54.76 ± 8.56
54.17 ± 10.99
0.999
Gender (Female %)
48%
52%
0.809
Years with T2D
6.48 ± 5.18
5.48 ± 5.93
0.478
Smoking (yes %)
10%
28%
0.091
2
BMI (kg/m )
34.72 ± 6.98
30.74 ± 4.93
0.013
A1C (%)
8.25 ± 2.40
8.26 ± 1.92
0.981
Continues variables are presented as mean ± SD and categorical variables as %.
25(OH)D: serum vitamin D, PTH: parathyroid hormone, T2D: type 2 diabetes, BMI:
body mass index, A1C: glycated hemoglobin.
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Table 2. Effect of vitamin D repletion treatments on serum vitamin D and parathyroid
hormone
Characteristic

Treatment
4000 IU
6000 IU
(n=50)
(n=25)

25(OH)D (ng/ml)
Baseline
3 months
P-value (baseline vs. 3 months)

22.25 ± 7.19
37.34 ± 12.31
0.001

23.74 ± 5.09
43.20 ± 15.94
0.001

6 months
P-value (baseline vs. 6 months)

37.99 ± 13.22
0.001

40.62 ± 19.39
0.001

Repletion of vitamin D
insufficiency ≥30ng/ml (%) at 3 months

68%

72%

Repletion of vitamin D
insufficiency ≥30ng/ml (%) at 6 months

70%

68%

38.60 ± 18.14
32.21 ± 20.59
0.103

41.42 ± 17.77
36.05 ± 14.48
0.247

Parathyroid hormone (pg/ml)
Baseline
3 months
P-value (baseline vs. 3 months)

6 months
36.66 ± 17.84 36.11 ± 18.78
P-value (baseline vs. 6 months)
0.592
0.309
Continues variables are presented as mean ± SD and categorical variables as %.
25(OH)D: serum vitamin D
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Table 3. Relationship between change in parathyroid hormone, change in
serum 25(OH)D and covariates at 3 months for the 4000 IU treatment
Parameter*
25(OH)D (ng/ml)
Age (years)

Β
-0.176
-0.428

SE
0.085
0.209

T
-2.062
-2.048

P-value†
0.045
0.047

*Other covariates in the multiple linear regression were gender, BMI,
years with type 2 diabetes, smoking and A1C. † P < 0.05 is considered
significant.

Table 4. Relationship between change in parathyroid hormone, change in
serum 25(OH)D and covariates at 6 months for the 4000 IU treatment
Parameter*
25(OH)D (ng/ml)
Age (years)

Β
-0.209
-0.449

SE
0.098
0.206

T
-2.134
-2.180

P-value†
0.039
0.035

*Other covariates in the multiple linear regression were gender, BMI,
years with type 2 diabetes, smoking and A1C. † P < 0.05 is considered
significant.
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CHAPTER V: VALIDATION OF A SUN EXPOSURE QUESTIONNAIRE IN
PARTICIPANTS WITH TYPE 2 DIABETES RESIDING IN SOUTH FLORIDA

Introduction
Low levels of vitamin D are prevalent in the US (1). According to data from the
National Health and Nutrition Examination Surveys (NHANES) in 2001-2006, 33% of
the general US population had serum 25(OH)D below 50 nmol/L. In addition, low
vitamin D levels are especially common among minorities. For instance, 41% of African
Americans and 33% of Mexican Americans had serum 25(OH)D below 50 nmol/L
compared to 18% of non-Hispanic Whites (1).
The sun is the main source of vitamin D. Ultraviolet B (UVB) radiation emitted
by the sun converts cholesterol into vitamin D in the skin. The avoidance of sun exposure
due to perceived skin cancer risk and the lack of outdoor physical activity due to a more
sedentary life may explain in part the current vitamin D deficiency epidemic (2).
Research is still in progress to quantify vitamin D status in specific populations
and its relation with several diseases. Therefore, the assessment of vitamin D status must
take into consideration sun exposure behaviors through the use of validated tools.
Sun exposure questionnaires are commonly used to assess UVB exposure because
they are easy to use and inexpensive. Observed sun exposure and dosimetry, an objective
measure of UVB radiation, have been used for comparison (3-6), however, neither of
them is considered a gold standard (7). The correlations among sun exposure
questionnaires and observed exposure or dosimetry have been significant but relatively
low, leaving a big percentage in the variation in UVB unexplained by sun exposure alone
(3-6).
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Similarly, when sun exposure questionnaires have been used in models to predict
25(OH)D (the universally accepted biomarker to determine vitamin D status) a large
percentage of the variation was not explained by sun exposure, which may lead to a
misclassification of vitamin D status if based on sun exposure alone (8-10).
On the other hand, objective and reliable measures of change in skin color using
scanners allow in vivo quantification and have shown significantly high correlations with
laboratory induced UVB exposure (r s = 0.99) (11). In addition, these devices offer high
inter/intra rater reliability (12). Therefore, they may be used as gold standard to validate
sun exposure questionnaires.
Type 2 diabetes (T2D) has increased dramatically in the United States (US)
among adults 20 years of age and older from 9% in 1988 to 11% in 2010. The increase
has been even more dramatic among African Americans from 16% in 1988 to 20% in
2010. In Mexican Americans the incidence has increased from 15% to 17% in the same
time period. Minorities, particularly African Americans and Hispanics, are
disproportionately afflicted by T2D compared to non-Hispanics Whites (13).
In addition, poor vitamin D status has been found in participants at risk (with
metabolic syndrome) and those with T2D. The nature of this relationship, however, is not
clear (14, 15). Similarly, an inverse association between vitamin D levels and insulin
resistance has been reported in a large sample representative of the US adult population
and in participants at risk for T2D (15, 16). According to these results vitamin D levels
are associated with insulin sensitivity and insulin resistance. Therefore, it is necessary to
validate sun exposure tools in order to accurately assess vitamin D status in minorities
with T2D.
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The objective of the present study was to validate a sun exposure questionnaire
against objective measures of change in skin color and to assess its validity in predicting
25(OH)D status in a sample of African Americans and Hispanics with T2D.

Methods
Participants
An intervention study to assess the effects of vitamin D supplementation (4000
IU/day and 6000 IU/day) over six months on cardiovascular markers among a sample of
African Americans and Hispanics with T2D was conducted. The present study analyzed
the data collected at screening.
The study consisted of two phases: phase one included the screening of
individuals, phase two included the recruitment of individuals who met inclusion criteria
and beginning of the vitamin D intervention trial. The inclusion criteria were vitamin D
insufficiency (25(OH)D < 30 ng/ml), 30-70 years of age, African American or Hispanic
with confirmed T2D. Exclusion criteria were taking vitamin D supplements other than
standard daily multivitamin formula, pregnant or lactating, having thyroid, hepatic, renal
dysfunction, cancer, HIV, and major psychiatric disorders.
Flyers explaining the purpose of the study, inclusion/exclusion criteria and
containing investigators’ emails and phone numbers were distributed in highly visited
community areas such as churches, supermarkets, and clinics. Two clinics were visited
every week for recruitment purposes: Borinquen Health Care Center and Clinical Care
Medical Center. When participants called the investigators, purposes of the study were
explained and specific questions were asked to assure compliance with inclusion criteria.
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All qualified participants were invited to participate in a morning session at Human
Nutrition Laboratory, AHC-1, room 430, Florida International University for fasting
blood sampling to screen for vitamin D insufficiency. All participants were asked to sign
an informed consent form previous to screening data collection and to provide contact
number and address of their physician, as well as their own contact information. Only
participants with T2D diagnosis confirmed by a physician were eligible to participate in
the study. The study was approved by IRB at FIU.
Participants in both groups were required to take either 4000 IU or 6000 IU of
vitamin D (Cholecalciferol) per day given in the form of a pill in a single daily dose.
Each participant was seen 4 times; at screening, baseline, 3 months, and 6 months. The
study lasted for 25 weeks for each participant from screening to final assessment. The
study started in June 2011 and completed on September 2013. Ninety two participants
were screened. Two subjects were excluded due to missing values for sun exposure
scores. The present study analyzed the data collected only at screening. Total sample size
was 90 participants.

Blood Collection
Venous blood (15 ml) was collected from each subject by a certified phlebotomist
using standard laboratory methods at each study point. After coagulation, blood was
centrifuged at 2500 RPM for 30 minutes. The plasma glucose concentration was
measured by hexokinase enzymatic method. Glycated hemoglobin (A1c) was measured
by the DCA2000+ system (Bayer Corporation, Diagnostics Division, N.Y.) using the
monoclonal antibody method. Serum vitamin D concentrations were measured with an
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enzyme-immunoassay kit by absorbance (Immunodiagnostic Systems Scottsdale, AZ).
Color intensity developed was inversely proportional to the concentration of serum
25(OH)D.

Socio-demographic Questionnaire
Participants were asked to fill out a standard questionnaire on site. Trained
interviewers bilingual in English and Spanish administered the questionnaires in the
language of preference of the participants. Data were collected using a sociodemographic questionnaire which includes questions related to gender, age, years living
in the US, years with diabetes, smoking, and alcohol intake.

Anthropometric Measurements
Height and weight were measured using a SECA clinical balance scale (Seca
Corp, Columbia, MD). Body mass index (BMI) was calculated as weight in kg/height in
m2.

Sun Exposure Questionnaire
The sun exposure questionnaire developed by Hanwell et al. (17) was used
following the original rubric. Time spent outdoors during the previous week (0≤5
minutes, 1=5-30 minutes and 2= >30 min) was self-reported. Four options for skin
exposed while outdoors were offered (1=face and hands, 2=face, hands and arms, 3=face,
hands and legs and 4=bathing suit). The daily sun exposure score for each day was
calculated by multiplying the time spent outdoors score times the skin exposed while
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outdoors score. The scale for each day ranged from 0 to 8. The weekly sun exposure was
calculated by adding the daily scores (min =0, max=56).

Skin Color
In order to have an objective measure of sun exposure, skin color was determined
by reflectance colorimetry using the SmartProbe 400 (IMS Inc. USA). This instrument
uses the International Commission on Illumination Scale which ranges from 0 (black) to
100 (white) for skin color. Two readings at each measurement site (6 readings total) for
each participant were taken: two on the dorsal aspect of the wrist of the right hand (area
most exposed to sun), two on the inside of the right upper arm and the stomach (areas less
exposed to the sun). The mean values of the two readings at each measurement site were
used for analysis. The change in skin color due to sun exposure was calculated by finding
the difference between the less exposed area (natural color) and the most exposed area.

Statistical analysis
Descriptive statistics for continuous variables were presented as mean ± SD and
proportions for categorical variables. Spearman’s correlation among weekly sun exposure
scores and delta of skin color, sun exposure scores, skin exposure score, forearm skin
color, stomach skin color, and change in skin color with 25(OH)D were run. The
relationship between serum 25(OH)D, skin exposure score and stomach skin color was
evaluated by a multiple linear regression model. Serum 25(OH)D was the dependent
variable. Skin exposure score and stomach skin color were independent variables. All of
the three variables were continuous. A simple model was run using skin exposure score
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and stomach skin color as predictors of serum 25(OH)D. Confounding factors including
age, gender, BMI, years living in US, years with type 2 diabetes, ethnicity, tobacco use
and alcohol consumption were added to the adjusted model. Two-way and three-way
interactions were tested between total skin exposure score, stomach skin color, and
gender. All of the analyses were conducted using SPSS version 19 (Chicago, IL, US).

Results
Analysis for sun exposure questionnaire validation included 92 participants.
Eighty four percent were vitamin D deficient. Two participants were excluded for
missing sun exposure scores. Final sample considered for the analysis included 90
participants, males (n=44, 49%), females (n=46, 51%). Descriptive characteristics are
provided in table I. The mean age was 54.8±9.7 years. The mean BMI was 33.7±6.6
kg/m2. The mean serum 25(OH)D (22.6±6.6 ng/ml), forearm skin color (55.7±7.5),
stomach skin color (59.2±9.8), change in skin color (3.5±5.4), total sun exposure score
(19.6±15.0), time outdoors score (6.5±4.6), skin exposure score (20.4±3.2), and A1C
(8.3±2.2%) are presented in table 1. The minimum and maximum scores for weekly sun
exposure, time outdoors, and skin exposure scores were 0 and 52, 0 and 14, 8 and 28,
respectively. About fourteen percent of the participants were African Americans and
eighty six percent Hispanics.
Correlations between weekly sun exposure and change in skin color or serum
25(OH)D were not significant (P=0.487, r s =0.081 and P=0.864, r s =0.020; respectively).
Correlations between skin exposure score, stomach skin color, and change in skin color
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with serum 25(OH)D were significant (P=0.047, r s =0.230; P=0.024, r s =0.260; and
P=0.015, r s =0.280; respectively) (Table 2).
The unadjusted model showed that skin exposure score (P= 0.037), and stomach
skin color (P= 0.021) were good predictors of serum 25(OH)D. In this model, 22 percent
of the variation in serum 25(OH)D was explained by skin exposure score and stomach
skin color. This relationship remained significant for stomach skin color (P= 0.020), but
not for skin exposure score (P=0.149) after controlling for covariates, including age,
gender, BMI, years living in US, years with T2D, ethnicity, tobacco use and alcohol
consumption. The fully adjusted model explained 38.1 percent of the variation in serum
25(OH)D. A1C was also significantly associated with serum 25(OH)D. For every unit
increase in stomach skin color, there was a 0.33 unit increase in serum 25(OH)D. In
contrast, for every unit increase in A1C, there was a 1.274 unit decrease in serum
25(OH)D, keeping the other variables constant (Table 3). Two and three-way
interactions between skin exposure scores, stomach skin color, and gender were not
significant.

Discussion
Sun exposure questionnaires are commonly validated against observed records of
sun exposure or dosimetry (3-6). However, none of them is considered a gold standard
(7). Serum 25(OH)D levels are indicators of sun exposure in the last two months (18-20).
Therefore, it has been used as gold standard in other studies. Similarly, colorimeters used
to determine skin color have significantly correlated with induced UV exposure (r=0.99)
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providing a more accurate gold standard tool to validate sun exposure questionnaires
(11,12).
The total weekly sun exposure score was not correlated with neither change in
skin color nor serum 25(OH)D in our study. These results are explained by the very short
time spent outdoors in this population of participants with T2D. In fact, 18 participants
spent less than 5 minutes outdoors every day, making the whole sun exposure score equal
to zero. When the skin exposure score alone is taken into consideration, it was
significantly correlated with serum 25(OH)D. Therefore, the tool developed by Hanwell
et al. (17) was not a good indicator of sun exposure in this population of participants with
T2D due to the limited time they spent outdoors. The population used by Hanweel et al.
(17) was active Caucasian hospital workers in Italy. However, the correlations between
sun exposure scores and serum 25(OH)D were only significant for summer but not for
winter, meaning that in times of limited sun exposure other tools should be used for
screening. In addition, the strongest component of the total sun exposure score was the
time spent outdoors. Time spent outdoors was significantly correlated with serum
25(OH)D despite the amount of skin exposed during summer (17). Therefore, the amount
of skin exposed is not important during summer. The main determinant of UV exposure
is the time spent outdoors.
Other studies have found significant but low correlations between self-reported
sun exposure and dosimetry (21,22). A study conducted in Australia compared sun
exposure behaviors from diaries to personal dosimetry in mothers (r=0.32) and children
(r=0.34) (21). Another study conducted in the US found different correlation between
self-reported sun exposure and dosimetry per body part (r=0.12 for the arm and r=0.49
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for the leg) (22). According to these data, the precision of UV exposure based on sun
exposure questionnaires is poor. Therefore, measurement errors should be included in the
models. To our knowledge, none of these instruments have been validated in older
participants with T2D. In addition, self-reported questionnaires are prone to recall bias. In
an older population, the bias may be even greater.
Regarding the use of sun exposure questionnaires to predict serum 25(OH)D, a
case-control study of multiple sclerosis found significant but low correlations for outdoor
activities in the past 3 years and serum 25(OH)D levels (r=0.39) (8). This means that
about 85% of the variation in serum 25(OH)D is not explained by sun exposure
behaviors. Another study found that the contribution of outdoor activities to serum
25(OH)D is important only in summer (10). According to these results, other variables
such as age and skin color should be included in models to screen for vitamin D status.
The original tool was validated in white individuals (17). Since natural skin color
have a profound impact on vitamin D synthesis and our population was Hispanics and
African Americans, it may be possible that the color of the skin is a better predictor of
serum 25(OH)D in this particular population than sun exposure behaviors.
In fact, unexposed skin color (stomach) and the difference between unexposed
and exposed areas (stomach and forearm) were significantly correlated with serum
25(OH)D. This is in contrasts with Nessvi et al. (23) who suggested that both unexposed
and exposed areas are good predictors of serum 25(OH)D. In our population, unexposed
skin color was the biggest determinant of serum 25(OH)D, meaning that the natural skin
color of the individual can predict vitamin D status. However, correlation was low
(r s =0.26) leaving a large proportion of the variation in serum 25(OH)D unexplained by
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unexposed skin color alone. Other factors like vitamin D intake from food and
supplements, type of clothing worn, and the months away from Florida may have been
important in the assessment of vitamin D status.
The unadjusted model using skin exposure score and stomach skin color as
independent variables was significant for both, but the model only explained 22% of the
variation in serum 25(OH)D. When the model was adjusted for covariates, only stomach
skin color remained significantly associated with serum 25(OH)D. The adjusted model
explained 38.1% of the variation in serum 25(OH)D, still leaving a big proportion
unexplained. It is unlikely that tanning behaviors or sunscreen use may have played a role
in serum 25(OH)D levels in this particular population.
Interestingly, A1C, a marker of the blood glucose control over the last 3 months,
was strongly associated with serum 25(OH)D. This may imply that in participants with
T2D with limited sun exposure, A1C levels may be an important marker to determine
vitamin D status.
Even though, the correlation between change in skin color (unexposed minus
exposed area) and serum 25(OH)D was significant, it was mainly driven by the
unexposed area. In fact, since outdoors activities were limited, the differences in skin
color between unexposed and exposed areas were minimal in many participants.
It is important to note that eighty four percent of our sample was vitamin D
deficient at screening. It is paradoxical that in a tropical area like South Florida the
incidence of vitamin D deficiency is still high among participants with T2D. Mean
weekly sun exposure score was 19.6 out of a total of 56, reflecting very limited sun
exposure. Alcohol intake and smoking can interfere with vitamin D absorption (7).
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However, the incidence for both of them (16% and 28%, respectively) was low. It seems
that the limited outdoor activity may explain in part the high incidence of deficiency in
our sample.
Limitations of our study include the small sample size, the high incidence of
vitamin D deficiency, the lack of data regarding vitamin D intake from foods and
supplements, and the limited outdoor activity of this particular sample.
The sun exposure questionnaire developed by Hanwell et al.(17) was not a valid
tool to estimate change in skin color due to sun exposure or serum 25(OH)D levels in this
sample of African Americans and Hispanics with T2D. Unexposed skin color and A1C
levels were significantly associated with serum 25(OH)D. Unexposed skin color may be
used as proxy measure to screen for vitamin D deficiency in this sample of participants
with T2D.
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Table 1. Characteristics of the study participants at screening (n = 90)
Variable
Mean ± SD
Age (years)
54.8 ± 9.7
BMI (kg/m2)
33.7 ± 6.6
Living in US (years)
10.4 ± 9.3
Serum 25(OH)D (ng/ml)
22.6 ± 6.6
Forearm skin color
55.7 ± 7.5
Stomach skin color
59.2 ± 9.8
Delta of skin color
3.5 ± 5.4
Sun exposure score
19.6 ± 15.0
Time outdoors score
6.5 ± 4.6
Skin exposure score
20.4 ± 3.2
A1C (%)
8.3 ± 2.2
FPG (mg/dl)
181.9 ± 78.3
Years with T2D
6.15 ± 5.4
Tobacco use
No
84.0 %
Yes
16.0 %
Alcohol consumption
No
72.0 %
Yes
28.0 %
Gender
females
51.1%
males
48.9%
Data are mean ± standard deviation (SD) or %.
BMI = Body mass index, A1C= glycated
haemoglobin, FPG= fasting plasma glucose,
T2D= type 2 diabetes
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Table 2. Correlation analysis (n = 90)
Variables compared
Sun exposure score vs. change in skin color
Sun exposure score vs. 25(OH)D
Skin exposure score vs. 25(OH)D
Forearm skin color vs. 25(OH)D
Stomach skin color vs. 25(OH)D
Change in skin color vs. 25(OH)D

rs

P-value

0.081
0.020
0.230
0.197
0.260
0.280

0.487
0.864
0.047
0.090
0.024
0.015

Table 3. Relationship of serum 25(OH)D and covariates
Parameter*
Stomach skin color
Skin exposure score
A1C (glycated hemoglobin)

Β
0.330
0.356
-1.274

SE
0.139
0.244
0.321

T
2.378
1.462
-3.967

P-value†
0.020
0.149
0.001

*Other covariates in the multiple linear regression were age, gender,
BMI, years living in US, years with type 2 diabetes, ethnicity, tobacco use
and alcohol consumption. † P < 0.05 is considered significant.

89

References
1. Centers for Disease Control and Prevention. Vitamin D Status: United States,
2001-2006. Accessed January 29, 2014. Available
http://www.cdc.gov/nchs/data/databriefs/db59.pdf
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
3. Vishvakarman D, Wong JCF, Boreham BW. Annual occupational exposure to
ultraviolet radiation in central Queensland. Health Phys 2001;81:536-544.
4. O’Riodan DL, Lunde KB, Steffen AD, Maddock JE. Validity of beach-goers’
self-report of their sun habits. Arch Dermatol 2006;142:1304-1311.
5. Diffey BL, Saunders PJ. Behavior outdoors and its effect on personal ultraviolet
exposure rate measured using an ambulatory data logging dosimeter. Photochem
Photobiol 1995;61:615-618.
6. Dwyer T, Blizzard L, Gies PH, Ashbolt R, Roy C. Assessment of habitual sun
exposure in adolescents via questionnaire-a comparison with objective
measurement using polysulphone badges. Melanoma Res 1996;6:231-239.
7. McCarty CA. Sunlight exposure assessment: can we accurately assess vitamin D
exposure from sunlight questionnaires? Am J Clin Nutr 2008;87:1097S-1101S.
8. Van der Maei IAF, Blizzard L, Ponsonby AL, Dwyer T. Validity and reliability of
adult recall of past sun exposure in a case-control study of multiple sclerosis.
Cancer Epidemiol Biomarkers Prev 2006;15:1538-1544.
9. Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sorensen OH. Vitamin
D status and its adequacy in healthy Danish perimenopausal women: relationships
to dietary intake, sun exposure, and serum parathyroid hormone. Br J Nutr
2001;86:S97-S103.
10. Pasco JA, Henry MJ, Nicholson GC, Sanders KM, Kotowicz MA. Vitamin D
status of women in the Geelong Osteoporosis Study: association with diet and
casual exposure to sunlight. Med J Aust 2001;175:401-405.
11. Andersen PH, Bjerring P. Spectral reflectance of human skin in vivo.
Photodermatol Photoimmunol Photomed 1990;7:5-12.
12. Glanz K, Mayer JA. Reducing ultraviolet radiation exposure to prevent skin
cancer methodology and measurement. American Journal of Preventive Medicine
2005;29:131-142.

90

13. Centers for Disease Control and Prevention. Health, United States, 2010.
Accessed January 29, 2014. Available
http://www.cdc.gov/nchs/data/hus/hus10.pdf#050
14. Baynes KCR, Boucher BJ, Feskens EJM, Kromhout D. Vitamin D, glucose
tolerance and insulinaemia in elderly men. Diabetologia. 1997;40(3):344-347.
15. Scragg R, Sowers M, Bell C. Serun 25-hydroxyvitamin D, diabetes, and ethnicity
in the Third National Health and Nutrition Examination Survey. Diabetes Care.
2004;27(12):2813-2818.
16. Kayaniyil S, Vieth R, Retnakaran R, Knight JA, Qi Y, Gerstein HC, et al.
Association of vitamin D with insulin resistance and β-cell dysfunction in subjects
at risk for type 2 diabetes. Diabetes Care. 2010;33(6):1379-1381.
17. Hanwell HE, Vieth R, Cole DE, Scillitani A, Modoni S, Frusciante V, et al. Sun
exposure questionnaire predicts circulating 25-hydroxyvitamin D concentrations
in Caucasian hospital workers in southern Italy. J Steroid Biochem Mol Biol.
2010;121(1-2):334-337.
18. Vieth R. The pharmacology of vitamin D, including fortification strategies. In:
Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. Vol. 2. 2nd ed. New
York: Elsevier; 2005. p. 995–1015.
19. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes.
Dietary reference intakes: calcium, phosphorus, magnesium, vitamin D, fluoride.
National Academy Press; 1997.
20. Hollis BW, Wagner CL, Drezner MK, Binkley NC. Circulating vitamin D3 and
25-hydroxyvitamin D in humans: An important tool to define adequate nutritional
vitamin D status. J Steroid Biochem Mol Biol. 2007;103(3-5):631-634.
21. O’Riordan DL, Stanton WR, Eyeson-Annam M, Gies P, Roy C. Correlations
between reported and measured ultraviolet radioation exposure of mothers and
young children. Photochem Photobiol 2000;71:60-64.
22. Yaroch AL, Reynolds KD, Buller DB, Maloy JA, Geno CR. Validity of a sun
safety diary using UV monitors in middle school children. Health Educ Behav
2006;33:340-351.
23. Nessvi S, Johansson L, Jopson J, Stewart A, Reeder A, McKenzie R, et al.
Association of 25-hydroxyvitamin D3 levels in adult New Zealanders with
ethnicity, skin color and self-reported skin sensitivity to sun exposure. Photochem
Photobiol. 2011;87(5):1173-1178.

91

CHAPTER VI: VALIDATION OF A SHORT FOOD FREQUENCY
QUESTIONNAIRE FOR THE ASSESSMENT OF VITAMIN D INTAKE IN
MINORITIES WITH TYPE 2 DIABETES

Introduction
Low levels of vitamin D are prevalent in the US (1). According to data from the
National Health and Nutrition Examination Surveys (NHANES) in 2001-2006, 33% of
the general US population had serum 25(OH)D below 50 nmol/L. In addition, studies
have shown that persons with darker skin color have lower vitamin D levels (2, 3). In
fact, low vitamin D levels are especially common among minorities. For instance, 41% of
African Americans and 33% of Mexican Americans had serum 25(OH)D below 50
nmol/L compared to 18% of non-Hispanic Whites (1).
Poor vitamin D status has been found in participants at risk or with type 2
diabetes (T2D), however, the nature of this relationship is not clear (4, 5). Similarly, a
negative association between vitamin D levels and insulin resistance has been reported in
a large sample representative of the US adult population and in participants at risk for
T2D (5, 6). According to these results, vitamin D levels are positively associated with
insulin sensitivity and negatively associated with insulin resistance.
Vitamin D level depends on several modifiable and non-modifiable factors. Skin
color is the major non-modifiable factor and modifiable factors include sun exposure and
vitamin D intake (7). However, there are no validated tools to assess vitamin D intake in
participants with type 2 diabetes.
Nutrient intake can be estimated by multiple methods, each of them presenting
their own advantages and disadvantages. Food records are usually considered the gold
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standard. They are administered over several days in order to represent usual intake.
However, due to the burden of writing down every food and portion size, the period is
limited (8). If the subject change his/her usual diet during this period, the data may be
misleading. In addition, a tendency to underreport food intake by obese and overweight
individuals have been reported (9). In contrast, food frequency questionnaires (FFQ) can
assess food intake over a longer period of time (usually over a 1 year), can be
administered by dietitians in situ or self-administered in a short period of time putting
less burden on participants and may expose habits not evident on food records (10).
However, FFQ should include ethnic specific foods and validated in the specific
population under study (10).
Several vitamin D FFQs have been validated in different populations, however, to
our knowledge; none have been validated in Hispanic and African American participants
with type 2 diabetes. Marshall et al. (8) validated the Iowa Study Targeted Nutrient SemiQuantitative Questionnaire and the Block Kids Food Questionnaire for estimating
calcium and vitamin D intake among children using a 3-day food diary as reference.
Correlations between the questionnaires and food diary for vitamin D were modest
(r=0.487 and r=0.512, respectively). Pritchard et al. (11) validated a calcium, vitamin D,
and vitamin K FFQ that also included assessment of supplement intake in overweight and
obese post-menopausal women against a 5-day diet record. A strong correlation between
the FFQ and the diet record for vitamin D was reported (r=0.89). Taylor et al. (10)
validated a FFQ for assessing calcium and vitamin D intake in adolescent girls with
anorexia nervosa against a 4-day food record. Strong correlations among the two diet
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collection methods for vitamin D was observed (r=0.78). The analysis was adjusted for
energy intake.
Nucci et al. (7) evaluated the effectiveness of a short FFQ in determining vitamin
D intake against a previously validated long FFQ in a population of 6 to 14 year old
children. Correlations among the questionnaires was modest at baseline and follow up
(r=0.35 and r=0.37, respectively). The study took into consideration the sun exposure
habits of the population. Blalock et al. (12) assessed the validity of a short calcium and
vitamin D FFQ among 27 university employees against a 7 day food diary and a
previously validated long FFQ. Vitamin D intakes from the food diary and short FFQ
were significantly correlated (r=0.72). The positive predictive value for identifying
participants with low vitamin D intake using a cutoff point of 200 IU/day was 100%.
It has been suggested that validation of nutrient intake should be conducted
against a previously validated diet record but also against a biomarker of nutrient status
(13). Vitamin D status is determined by serum 25(OH)D levels. However, since UVB
light is the major contributor of vitamin D, validation studies should be conducted during
winter where 25(OH)D will be mainly affected by intake and not sun exposure.
Otherwise, sun exposure should be taken into consideration in the analysis of vitamin D
intake and 25(OH)D.
In this regard, Wu et al. (13) validated a 37-item vitamin D FFQ among a
multiethnic sample of Canadian adults during late winter against a 7-day food diary and
25(OH)D levels. Intakes were modestly correlated among dietary collection methods and
25(OH)D (r=0.529 and r=0.481, respectively). After redefining the serving sizes and
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excluding fortified orange juice from the FFQ, the correlations improved (r=0.602 and
r=0.520, respectively).
Since studies suggested that vitamin D deficiency may have a role on insulin
resistance and type 2 diabetes progression, it is imperative to validate diet collection tools
in this particular population. The objective of the present study was to expand the short
FFQ developed by Blalock et al (12). to include specific ethnic foods consumed by
Hispanics and African Americans in South Florida and to examine the criterion validity
of the short FFQ by comparing intakes with a previously validated long FFQ and serum
25 (OH) levels.

Methods
Participants
An intervention study to assess the effects of vitamin D supplementation (4000
IU/day and 6000 IU/day) over six months on cardiovascular disease markers among a
sample of African Americans and Hispanics with T2D was conducted. The present study
analyzed the data collected at screening (short FFQ, 25(OH)D, sun exposure, and skin
color) and baseline (long FFQ).
The study consisted of two phases: phase one included the screening of
individuals, phase two included the recruitment of individuals who met inclusion criteria
and beginning of the vitamin D intervention trial. The inclusion criteria were vitamin D
insufficiency (25(OH)D< 30 ng/ml), 30-70 years of age, African American or Hispanic
with confirmed T2D. Exclusion criteria were taking vitamin D supplements other than
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standard daily multivitamin formula, pregnant or lactating, having thyroid, hepatic, renal
dysfunction, cancer, HIV, and major psychiatric disorders.
Flyers explaining the purpose of the study, inclusion/exclusion criteria and
containing investigators’ emails and phone numbers were distributed in highly visited
community areas such as churches, supermarkets, and clinics. Two clinics were visited
every week for recruitment purposes: Borinquen Health Care Center and Clinical Care
Medical Center. When participants called the investigators, purposes of the study were
explained and specific questions were asked to assure compliance with inclusion criteria.
All qualified participants were invited to participate in a morning session at Human
Nutrition Laboratory at FIU for fasting blood sampling to screen for vitamin D
insufficiency. All participants were asked to sign an informed consent form previous to
screening data collection and to provide contact number and address of their physician, as
well as their own contact information. Only participants with T2D diagnosis confirmed
by a physician were eligible to participate in the study. The study was approved by IRB
at FIU.
Participants in both groups were required to take either 4000 IU or 6000 IU of
vitamin D (Cholecalciferol) per day given in the form of a pill in a single daily dose.
Each participant was seen 4 times; at screening, baseline, 3 months, and 6 months. Serum
25(OH)D were measured at screening, 3 months, and 6 months. The study lasted for 25
weeks for each participant from screening to final assessment. The study started in June
2011 and was completed on September 2013. Ninety two participants were screened.
Seventy five qualified for the intervention (n=50 for 4000 IU/day treatment and n=25 for
6000 IU/day treatment). The time frame between dietary data collection was one week
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(short FFQ at screening and long FFQ at baseline). Serum 25(OH)D, skin color and sun
exposure data collected at screening (before any treatment took place) was used for this
analysis. Even though data from the short FFQ, skin color, sun exposure, and serum
25(OH)D was available for the ninety two initial participants at screening, only the data
from the seventy five who qualified for the study and also completed the long FFQ at
baseline were included in the analysis.

Blood Collection
Venous blood (15 ml) was collected from each subject by a certified phlebotomist
using standard laboratory methods at each study point. After coagulation, blood was
centrifuged at 2500 RPM for 30 minutes. The plasma glucose concentration was
measured by hexokinase enzymatic method. Glycated hemoglobin (A1C) was measured
by the DCA2000+ system (Bayer Corporation, Diagnostics Division, N.Y., U.S.) using
the monoclonal antibody method. Serum vitamin D concentrations were measured with
an enzyme-immunoassay kit by absorbance (Immunodiagnostic Systems Scottsdale,
A.Z., U.S.). Color intensity developed was inversely proportional to the concentration of
serum 25(OH)D.

Socio-demographic Questionnaire
Participants were asked to complete a standard questionnaire on site. Trained
interviewers bilingual in English and Spanish administered the questionnaires in the
language of preference of the participant. Data were collected using a socio-demographic
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questionnaire which included questions related to gender, age, years with T2D, smoking,
alcohol intake, and years living in the US.

Anthropometric Measurements
Height (m) and weight (kg) were measured using a SECA clinical balance scale
(Seca Corp, Columbia, MD). Body mass index (BMI) was calculated as weight in
kg/height in m2.

Sun Exposure Questionnaire
The sun exposure questionnaire developed by Hanwell et al. (14) was used
following the original rubric. Time spent outdoors during the previous week (0≤5
minutes, 1=5-30 minutes and 2= >30 min) was self-reported. Four options for skin
exposed while outdoors were offered (1=face and hands, 2=face, hands and arms, 3=face,
hands and legs and 4=bathing suit). The daily sun exposure score for each day was
calculated by multiplying the time spent outdoors score times the skin exposed while
outdoors score. The scale for each day ranged from 0 to 8. The weekly sun exposure was
calculated by adding the daily scores (min =0, max=56).

Skin Color
In order to have an objective measure of sun exposure, skin color was determined
by reflectance colorimetry using the SmartProbe 400 (IMS Inc. USA). This instrument
uses the International Commission on Illumination Scale which ranges from 0 (black) to
100 (white) for skin color. Two readings at each measurement site (6 readings total) for
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each participant were taken: two on the dorsal aspect of the wrist of the right hand (area
most exposed to sun), two on the inside of the right upper arm and two on the stomach
(areas less exposed to the sun). The mean values of the two readings at each measurement
sites were used for analysis. The change in skin color due to sun exposure was calculated
by finding the difference between the less exposed area (natural color) and the most
exposed area.

Assessment of Dietary Intake
Dietary intake was determined using the long FFQ developed by Walter Willett
(15). This FFQ has been validated in different ethnical groups and, also, specifically in
Cuban-Americans in South Florida (16). Participants self-reported the average
consumption of specific amount of foods over the past 12 months. Frequencies ranged
from “never” to “six or more servings per day”. The FFQ also assessed the frequency use
of multivitamin/mineral supplements, salt, sugar, alcohol and vitamin D intake. A short
FFQ containing 24 foods and beverages designed to assess vitamin D and calcium intake
was administered during the screening phase. The original questionnaire contained only
22 foods (12). Pizza and sardines were added as common foods consumed by this
population based on our previous studies (16, 17). The questionnaire asked participants
how frequently they consume each food and the serving size. Total vitamin D intake was
calculated following the original rubric (12).
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Statistical Analysis
The descriptive statistics for continuous variables were presented as mean±SD
and proportions for categorical variables. The Student’s t test for paired samples was used
to compare the vitamin D intake between both questionnaires. Pearson correlations
among the long FFQ and short FFQ and the short FFQ and serum 25(OH)D was
conducted to test the validity of the questionnaire. A cross classification analysis was run
to determine the agreement between the questionnaires or if they misclassify participants
into categories based on vitamin D intake levels. For this purpose vitamin D intakes were
divided into quartiles. The proportion of participants who were classified into the same
quartile, same ± 1 quartile, or who were entirely misclassified when comparing both tools
was calculated. The positive predictive value of the short FFQ to identify participants
with vitamin D intake below the RDA (600 IU for people 1 to 70 years old) (18) was
determined comparing the number of individuals below the cutoff for each dietary
collection method. A multiple linear regression model was run to determine the
association between serum 25(OH)D, vitamin D intake from the short FFQ, and sun
exposure score. Serum 25(OH)D was the dependent variable. Later the model was
adjusted for age, gender, BMI, forearm skin color, A1C, years with T2D, years living in
the US, ethnicity, alcohol intake, and smoking status. All analyses were performed using
SPSS version 19 (Chicago, IL, US).A p-value of <.05 was considered significant.

Results
Participants (n=75) had a mean ± SD for age of 54.8 ± 9.7 years, BMI of 33.7 ±
6.6 kg/m2, serum 25(OH)D of 22.6 ± 6.6 ng/ml, forearm skin color of 55.7 ± 7.5, sun
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exposure score of 19.6 ± 15, A1C of 8.3 ± 2.2%, and fasting plasma glucose of 181.9 ±
78.3 mg/dl. They had been living in the US for 10.4 ± 9.3 years and have been diagnosed
with T2D for 6.1 ± 5.4 years (Table 1). Sixteen percent were smokers, 28% consumed
alcohol, 48.9% were males, and 86.7% were Hispanics. Dietary vitamin D intake
according to the long FFQ and short FFQ were 311.8 ± 241.8 and 323.7 ± 290.9 IU/day,
respectively (Table 1).
There were no significant differences between dietary vitamin D intake derived
from the long FFQ and the short FFQ (P=0.637). The mean difference between intakes
was 11.9 IU/day. The correlation between dietary methods was 0.683 (P<0.001). The
correlation between vitamin D intake according to the short FFQ and serum 25(OH)D
was not significant (r=0.010, P=0.934). The long FFQ was not correlated to serum
25(OH)D either (r=0.164, P=0.161) (Table 2).
The cross-classification analysis showed that 79% of the participants were
classified into the same quartile by both collection methods and a 100% were classified
into the same ± 1 quartile. None of the participants was misclassified (Table 3).
The positive predictive value of the short FFQ to identify participants with
vitamin D intake below the RDA (600 IU/day) as compared to the long FFQ was 95.2%.
The unadjusted multilinear regression showed that short FFQ was not associated
with serum 25(OH)D (P=0.065). In contrast, sun exposure score was significantly
associated with serum 25(OH)D (P=0.020). The unadjusted model explained 9.7% of the
variation in serum 25(OH)D. When the model was adjusted for covariates, only A1C and
years with T2D were significantly associated with serum 25(OH)D (P<0.001 and
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P=0.028, respectively). The adjusted model explained 41% of the variation in serum
25(OH)D (Table 4).

Discussion
Food frequency questionnaires are used in clinical settings to record dietary
patterns over a long period of time. They can show patterns that are not detected with
food records and put less burden on the subject.
The FFQ developed by Willet et al. (15) has been commonly used in research
settings and validated in several populations. This questionnaire has 126 food items and
takes 45 minutes to be completed which is not practical in clinical settings. In contrast,
the short FFQ used in the present study has only 24 food items and takes 5 minutes to be
completed (12).
In fact, the short FFQ was valid when compared to the long FFQ. The correlation
obtained between questionnaires (r=0.683) was higher than the one obtained by Nucci et
al. (r=0.35) (7) when validating a 21-item short FFQ against a 152-item long FFQ among
14 year old children. The reason for this low correlation may be that the information was
provided by the parents and that supplement intake was assumed to be 400 IU when it
was not specified (7). Studies that used food records as the gold standard to validate short
FFQ have obtained higher correlations. Pritchard et al. (11) validated a calcium, vitamin
D, and vitamin K FFQ in overweight and obese post-menopausal women against a 5-day
diet record. A strong correlation between the FFQ and the diet record for vitamin D was
reported (r=0.89). Taylor et al. (10) validated a FFQ for assessing calcium and vitamin D
intake in adolescent girls with anorexia nervosa against a 4-day food record. Strong
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correlations among the two diet collection methods for vitamin D was observed (r=0.78).
Blalock et al. (12), who developed the questionnaire that was used in the current study,
validated the tool against a 7 day food diary. Vitamin D intakes from the food dairy and
short FFQ were significantly correlated (r=0.72).
It may be possible that the use of a gold standard collection method like food
records increased the correlation with the short FFQ in the previous studies compared to
this study due to less variability. However, the food records are only collected during a
short period of time and it is assumed that they represent real intake. Therefore, all errors
in intake are assigned to the short FFQ when compared to food records. If some unusual
foods are consumed during these days, then the food records no longer represent a real
intake and a systemic bias is added to the analysis which does not happen when a short
FFQ is validated against a long FFQ.
In addition, none of the participants was grossly misclassified when the sample
was divided in quartiles for both questionnaires. Therefore, the short FFQ can accurately
classify participants according to their vitamin D intake.
Even though the mean difference in vitamin D intake reported by both tools was
not significant, the short FFQ over reported vitamin D by 12 IU/day compared to the long
FFQ. This was expected since the short FFQ only focuses on foods containing vitamin D
while the long FFQ assesses all foods eaten over one year.
Blalock et al. (12), reported a positive predictive value of 100% when using a
cutoff point of 200 IU/day. In our study the positive predictive value to detect
participants with intakes below 600 IU/day was 95.2% which was expected because the
cut off was higher than the one used in the previous study. In addition, only 12% of our
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sample had intakes above 600 IU/day. This was also expected because our study only
enrolled participants with vitamin D insufficiency which makes our results not
generalizable to the entire population of patients with T2D. However, since vitamin D
insufficiency is prevalent among patients with T2D (5), this tool may be applicable to a
vast majority of this population.
The mean BMI of our sample was 33.7 ± 6.6 kg/m2, which may have affected our
results. It has been shown that obese participants underreport food intake despite the
collection method used (9). The majority of participants in our sample were overweight
and obese. Therefore, it is possible that actual vitamin D intake is higher and a correction
factor may be needed to approximate this value. Regarding ethnicity, only 10 African
Americans were enrolled in the study. Therefore, it was not possible to detect ethnic
differences due to the small sample size.
Diffey et al. (19), proposed a model to estimate serum 25(OH)D based on vitamin
D intake and sun exposure scores in Caucasian British adults. Even though, the model
was significant, it has been criticized for not including other important factors that affects
serum vitamin D levels. In fact, as we age vitamin D synthesis decreases and vitamin D is
sequestered in fat tissue (7). Therefore, age and BMI should be added to the model in
order to better represent the relationship with serum 25(OH)D.
In this regard, the correlation between the short FFQ vitamin D intake and serum
25(OH)D was not significant in our sample. We hypothesised that adding the sun
exposure questionnaire was going to improve the relationship. A more careful view of the
sun exposure scores revealed that a considerable proportion of the participants in our
sample spend no time at all outdoors. Therefore, this was not a sample with enough
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variability in sun exposure habits. When age and BMI were added to the model, they did
not contribute significantly to the association either. Interestingly, time with T2D and
A1C were strongly associated with serum 25(OH)D. To our knowledge, there was no
study validating a short vitamin D food frequency questionnaire in participants with T2D
in the literature, thus, we were unable to compare our results. It may be possible that in
participants with T2D, vitamin D levels are related to insulin sensitivity and to blood
glucose. Therefore, supplementing vitamin D to participants with T2D may have a
profound impact on glycemic control, despite sun exposure habits or intake.
We were not able to adjust for kcal intake because the short FFQ does not provide
energy intake data. However, there was no correlation between energy intake and vitamin
D intake in the long FFQ, which makes us think that energy intake is not a confounder in
this particular sample.
Our study has additional limitations. The short FFQ did not include fortified foods
like orange juice, meats, and soy milk. In addition, supplement intake was not recorded in
the short FFQ. This short FFQ should be administered several times a year to track the
vitamin D intake change between seasons.
Finally, this is the first short FFQ designed to asses vitamin D intake validated in
a population of participants with T2D. This tool is easy to use in clinical settings due to
its brevity and simplicity. In addition, it can help screen participants at high risk of
vitamin D deficiency that can be confirmed later with biochemical analysis. Since
glycemic control may be related to vitamin D status, screening for vitamin D deficiency
using this short FFQ may help prevent diabetes complications in Hispanics and African
Americans.
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Table 1. Characteristics of the study participants (n = 75)
Variable
Mean± SD
Age (years)
54.8 ± 9.7
BMI (kg/m2)
33.7 ± 6.6
Living in US (years)
10.4 ± 9.3
Serum 25(OH)D (ng/ml)
22.6 ± 6.6
Forearm skin color
55.7 ± 7.5
Stomach skin color
59.2 ± 9.8
Delta of skin color
3.5 ± 5.4
Sun exposure score
19.6 ± 15.0
Time outdoors score
6.5 ± 4.6
Skin exposure score
20.4 ± 3.2
A1C (%)
8.3 ± 2.2
FPG (mg/dl)
181.9 ± 78.3
6.1 ± 5.4
Years with T2D
Dietary Vit D intake (long FFQ)(IU/day)
311.8 ± 241.8
Dietary Vit D intake (short FFQ)(IU/day)
323.7 ± 290.9
Tobacco use
No
84.0 %
Yes
16.0 %
Alcohol consumption
No
72.0 %
Yes
28.0 %
Gender
Females
51.1%
48.9%
Males
Ethnicity
African Americans
13.3%
Hispanics
86.7%
Data are mean ± standard deviation (SD) or %. BMI = Body
mass index, A1C= glycated haemoglobin, FPG= fasting
plasma glucose, T2D= type 2 diabetes, FFQ = food frequency
questionnaire
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Table 2. Dietary vitamin D intake derived from the long FFQ and short FFQ, and
correlation between methods
Long FFQ
(Mean ±SD)
311.8 ± 241.8

Short FFQ
(Mean ± SD)
323.7 ± 290.9

P-value

Pearson r

Dietary Vitamin D
0.637
0.683*
intake (IU/day)
Significant differences between dietary sources determined by paired samples ttest. *Indicates significant correlation between long FFQ and short FFQ, P<0.05

Table 3. Cross-classification analysis to determine proportion of participants classified
into the same, or same ± 1 quartile based on short FFQ and long FFQ intakes.
% classified into
% classified into
% misclassified
same quartile
same ± 1 quartile
Vitamin D intake
79
100
0
Quartiles 1 to 4 for short FFQ were <140, 140-212, 212-486, >486 IU/day; quartiles 1 to
4 for long FFQ were <133.4, 133.4-245.3, 245.3-443.7, >443.7 IU/day. FFQ=short food
frequency questionnaire.
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Table 4. Relationship of serum 25(OH)D, dietary vitamin D intake, and
covariates
Parameter*
Vitamin D intake (short FFQ)
Sun exposure score

β
0.004
0.370

SE
0.003
0.224

T
1.48
1.65

P-value†
0.144
0.104

*Other covariates in the multiple linear regression were age, gender,
BMI, forearm skin color, A1C, years living in US, years with type 2
diabetes, ethnicity, tobacco use and alcohol consumption. † P< 0.05 is
considered significant.
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CHAPTER VII: SUMMARY AND CONCLUSIONS

Effect of vitamin D supplementation on blood lipids
In the current study, vitamin D 3 supplementation at 6000 IU/day significantly
reduced total cholesterol, and triglycerides in a sample of Hispanics and African
Americans with type 2 diabetes and vitamin D insufficiency. The significance was lost,
however, after adjusting for confounders. Therefore, our results suggest that the
association between vitamin D insufficiency and dyslipidemia may be mediated by other
cardiovascular risk factors such as obesity.
In addition, the positive effect of vitamin D supplementation on total cholesterol
and triglycerides was observed only in the 6000 IU group despite both groups reaching
similar serum vitamin D levels. It might be that sufficient vitamin D status was achieved
sooner in the 6000 IU/group and participants were exposed to sufficient vitamin D levels
for a longer period of time.

Effect of vitamin D supplementation on glucose homeostasis
Our results did not support the hypothesis that vitamin D supplementation may
improve glucose homeostasis in participants with established type 2 diabetes. Our
participants had 6.48 ± 5.18 and 5.48 ± 5.93 years with type 2 diabetes for the 4000 IU
and 6000 IU groups, respectively. This may indicate that vitamin D supplementation has
no effect on glucose homeostasis once beta cell function has passed a certain point of
deterioration.
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A trend for a decline in fasting plasma glucose was observed in the 4000 IU
group. Since no improvement was observed in A1C, a marker of long term glycemic
control, changes in fasting plasma glucose may be of limited significance in this
population with established type 2 diabetes.

Vitamin D repletion
Treatments with 4000 IU/day and 6000 IU/day increased serum 25(OH)D levels
significantly at 3 months and 6 months compared to baseline values. These results
support the notion that 4000 IU/day for 3 months is an adequate dosage to replenish
vitamin D in Hispanics and African Americans with T2D. Additional treatment for 3
extra months or a higher dosage of 6000 IU/day did not change serum 25(OH)D levels
significantly. According to these data, a physiological plateau is reached at 3 months with
the use of the 4000 IU/day regimen.
Regarding safety, none of the participants in our study reported any adverse
events or achieved a serum 25(OH)D > 150 ng/ml. Therefore, it seems that both
treatments are safe to use among this particular population of Hispanics and African
Americans with T2D for six months.

Validation of sun exposure questionnaire
The total weekly sun exposure score was not correlated with either change in skin
color or serum 25(OH)D in our study. These results are explained by the very short time
spent outdoors in this population of participants with T2D. The sun exposure
questionnaire was not a valid tool to estimate change in skin color due to sun exposure or
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serum 25(OH)D levels in this sample of African Americans and Hispanics with T2D.
Unexposed skin color and A1C levels were significantly associated with serum 25(OH)D.
Unexposed skin color may be used as proxy measure to screen for vitamin D deficiency
in this sample of participants with T2D.

Validation of a short food frequency questionnaire
The short FFQ demonstrated to be valid when compared to the long FFQ. In
addition, none of the participants was grossly misclassified when the sample was divided
in quartiles for both questionnaires. Therefore, the short FFQ can accurately classify
participants according to their vitamin D intake. The positive predictive value of the short
FFQ to detect participants with intakes below 600 IU/day was 95.2%.
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CHAPTER VIII: STRENGTHS AND LIMITATIONS

Our study had several strengths. First, to our knowledge this was the first study
that analyzed vitamin D supplementation effects on cardiovascular risk factors in
Hispanics and African Americans with T2D. Second, the dosages used were large enough
to raise serum vitamin D to sufficient levels in a population that was insufficient at
baseline. Third, analysis was adjusted for a wide range of covariates related to vitamin D
metabolism. Fourth, our study had sufficient power to find changes in fasting plasma
glucose, fasting insulin, A1C and lipid panel. Fifth, individuals did not change
medication, vitamin D intake, BMI, smoking or sun exposure habits during the course of
the study. Sixth, the short FFQ is the first validated tool to assess vitamin D intake in a
population of participants with T2D. This tool is easy to use in clinical settings due to its
brevity and simplicity. In addition, it can help screen participants at high risk of vitamin
D deficiency that can be confirmed later with biochemical analysis. Lastly, compliance in
our study was high with 94% for the 4000 IU group and 92% for the 6000 IU group
without any differences between groups. No adverse events were reported during the
course of the study.
Limitations of our study included: first, the sample was not representative of the
general population of people with T2D in the US and participants were not randomly
distributed among groups. Thus, our results are not generalizable. Second, our sample
was categorized as obese according to their BMI which may diminish the effect of
vitamin D supplementation. In addition, obese participants are prone to underreport food
intake. Third, the number of African American participants was not large enough to
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analyze data by ethnicity. Fourth, the use of fixed time intervals. Therefore, the peak
levels of serum 25(OH)D may have been missed. Fifth, the limited outdoor activity of
this particular sample. Sixth, the short FFQ did not include vitamin D fortified foods.
Lastly, 64% and 68% of participants were taking lipid lowering medication in the 4000
IU and 6000 IU groups, respectively. Medication use may mask the effect of vitamin D
supplementation. We tried to control for it by advising participants to keep their
medication use constant during the study, however, this panorama reflects common
clinical practice among patients with type 2 diabetes.
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CHAPTER IX: FUTURE RESEARCH

Our results suggest that the positive effect of vitamin D supplementation on lipid
profile may be mediated by other cofactors related to vitamin D metabolism among
Hispanic and African American participants with type 2 diabetes. The inclusion of
obese/non obese participants is needed in order to assess the confounding effect of this
variable. Longer, well designed randomized clinical trials are warranted.
The main objective of glycemic control in patients with type 2 diabetes is to
prevent microvascular and macrovascular complications. The use of surrogate measures
like fasting plasma glucose, insulin resistance, and A1C are of practical clinical
significance but not ideal for research purposes. Longer and larger studies supplementing
vitamin D to participants with type 2 diabetes that focus on microvascular and
macrovascular complications, instead of surrogate measures, are needed to confirm our
results.
It may be possible that maintenance of sufficient serum 25(OH) levels for a
longer period of time are needed to see significant changes in metabolic markers not
related to bone turn over or calcium metabolism. Therefore, it remains to be seen if
supplementation periods longer than 6 months may have an effect on cardiovascular risk
factors in this particular sample of Hispanics and African Americans with T2D.
Finally, the short FFQ is easy to use in clinical settings due to its brevity and
simplicity. In addition, it can help screen participants at high risk of vitamin D deficiency
that can be confirmed later with biochemical analysis. Therefore, studies testing the short
FFQ in community and clinical settings are warranted.
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Appendix 1: Consent Forms
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Appendix 2: Sun Exposure Questionnaire
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Sun Exposure Questionnaire.

Visit:_________Date:_____________ID#:__________

Please check the boxes that best describes your behavior
Time Outdoors
< 5min

5-30 min

>30 min

Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
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Hands
and face

Amount of Skin Exposed
Hands,
Hands
Bathing
face,
face, and Suit
and
legs
arms

Appendix 3: Short Food Frequency Questionnaire
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Appendix 4: Skin Color and Anthropometrics Control Form
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Appendix 5: Demographic Questionnaire
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Appendix 6: Compliance and Adverse Events Form
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